\chapter{Synthetic Lethal Analysis of Gene Expression Data}
\label{chap:SLIPT}

Having developed a statistical synthetic lethal detection methodology, \gls{SLIPT}, it was then applied to publicly available cancer gene expression datasets. The analysis focuses on breast cancer for which  \gls{TCGA} expression data \citep{TCGA2012} from a patient cohort and \gls{siRNA} screen data \citep{Telford2015} from experiments conducted in MCF10A cells were available. Stomach cancer data \citep{TCGA2014GC} was used to replicate findings in an independent dataset, with this cancer chosen because it also occurs in syndromic \gls{HDGC} patients. The \gls{TCGA} data also has the advantages of other clinical and molecular profiles including somatic mutation across many of the same samples, in addition to a considerable sample size for RNASeq expression data generated with a common \gls{TCGA} procedures to minimise batch effects. %Some findings were replicated in the Cancer Cell Line Encyclopaedia (CCLE) \citep{Barretina2012} for comparison to the cell line experiments.

Synthetic lethal candidate partners for \textit{CDH1} were identified at both the gene and pathway level. \gls{SLIPT} gene candidates were analysed by cluster analysis for common expression profiles across samples and relationships with clinical factors and mutations in key breast cancer genes. These genes will also be compared to the gene candidates from a primary and secondary (validation) screens conducted by \citet{Telford2015} on isogenic cell lines. For comparison, the \gls{SLIPT} methodology was also applied using mutation data for \textit{CDH1} against expression of candidate partners (as described in Section~\ref{methods:SLIPT}) which may better represent the null mutations in HDGC patients and the experiment cell model \citep{Chen2014}. Pathways were analysed by over-representation analysis (with resampling for comparisons with \gls{siRNA} data) and supported by a metagene analysis of pathway gene signatures. The pathway metagene expression profiles were used to replicate known relationships between clinical and molecular characteristics for breast cancer and to demonstrate application of \gls{SLIPT} directly on metagenes to detect synthetic lethal pathways.

Together these results demonstrate the wide range of applications for \gls{SLIPT} analysis and examine the synthetic lethal partners of \textit{CDH1} in breast and stomach cancer. These synthetic lethal genes and pathways were identified both in the context of the functional implications of novel synthetic lethal relationships and as potential actionable targets against \textit{CDH1} deficient tumours, in addition to replication of established functions of E-cadherin. In particular, these analyses focused on comparisons with experimental screening data to explore the potential for \gls{SLIPT} to augment triage of candidate partners and support further experimental investigations. The key synthetic lethal partner pathways for \textit{CDH1}, supported by both approaches, will be examined in more detail at the gene and pathway structure level in Chapter~\ref{chap:Pathways}.

Some of the findings presented in this Chapter have also been included in manuscripts submitted for publication \citep{KellyHDGC, KellyBMC} and may bear similarity to them, although the results in this thesis have been edited to cohesively fit with additional findings (including consistent data versions). These findings are the result of investigations conducted throughout this thesis project and only these contributions to the articles are included in this Chapter, not that conducted by co-authors.

\section{Synthetic Lethal Genes in Breast Cancer} \label{chapt3:exprSL_genes}

The \gls{SLIPT} methodology (as described in Section~\ref{methods:SLIPT}) was applied to the normalised TCGA breast cancer gene expression dataset ($n = 1168$). As shown in Table~\ref{tab:gene_SL}, the most significant genes had strong evidence of expression-based association with \textit{CDH1} (high $\chi^2$ values) with fewer samples exhibiting low expression of both genes than expected statistically. Eukaryotic translation genes were among the highest scoring gene candidates, including initiation factors, elongation factors, and ribosomal proteins. These are clearly necessary for cancer cells to grow and proliferate, with sustained gene expression needed to maintain growth signalling pathways and resist apoptosis or immune factors translation may be subject to non-oncogene addiction for \textit{CDH1}-deficient cells.

While these are among the strongest synthetic lethal candidates, translational genes are cruicial to the viability of healthy cells and dosing for a selective synthetic lethal effect against these may be difficult compared to other biological functions which may also be supported among the \gls{SLIPT} candidate genes. Furthermore, few known biological functions of \textit{CDH1} were among the strongest SL candidates, so the remaining candidate genes may also be informative since they are likely to contain these expected functions in addition to novel relationships for \textit{CDH1}. Thus further pathway level analyses were also conducted to examine biological functions over-represent\-ed among synthetic candidate genes and to identify synthetic lethal pathways.

\begin{table*}[!ht]
\caption{Candidate synthetic lethal gene partners of \textit{CDH1} from SLIPT}
\label{tab:gene_SL}
\centering
\resizebox{0.8 \textwidth}{!}{
\begin{threeparttable}
\begin{tabular}{>{\em}sl^c^c^c^c^c}
\rowstyle{\bfseries}
 \em{Gene} & Observed & Expected & $\chi^2$ value & p-value & p-value (FDR) \\ 
  \hline
  \rowcolor{black!10}
TRIP10 & 62 & 130 & 162 & $5.65 \times 10^{-34}$ & $1.84 \times 10^{-31}$ \\
  \rowcolor{black!5} 
  EEF1B2 & 56 & 130 & 158 & $3.10 \times 10^{-33}$ & $9.45 \times 10^{-31}$ \\
  \rowcolor{black!10} 
  GBGT1 & 61 & 131 & 156 & $1.08 \times 10^{-32}$ & $3.14 \times 10^{-30}$ \\
  \rowcolor{black!5} 
  ELN & 81 & 130 & 149 & $3.46 \times 10^{-31}$ & $8.82 \times 10^{-29}$ \\
  \rowcolor{black!10} 
  TSPAN4 & 78 & 130 & 146 & $1.63 \times 10^{-30}$ & $3.79 \times 10^{-28}$ \\
  \rowcolor{black!5} 
  GLIPR2 & 72 & 130 & 146 & $1.68 \times 10^{-30}$ & $3.86 \times 10^{-28}$ \\
  \rowcolor{black!10} 
  RPS20 & 73 & 131 & 145 & $1.89 \times 10^{-30}$ & $4.28 \times 10^{-28}$ \\
  \rowcolor{black!5} 
  RPS27A & 80 & 130 & 143 & $5.53 \times 10^{-30}$ & $1.18 \times 10^{-27}$ \\
  \rowcolor{black!10} 
  EEF1A1P9 & 63 & 130 & 141 & $1.91 \times 10^{-29}$ & $3.74 \times 10^{-27}$ \\
  \rowcolor{black!5} 
  C1R & 73 & 130 & 141 & $2.05 \times 10^{-29}$ & $3.97 \times 10^{-27}$ \\
  \rowcolor{black!10} 
  LYL1 & 73 & 130 & 140 & $2.99 \times 10^{-29}$ & $5.74 \times 10^{-27}$ \\
  \rowcolor{black!5} 
  RPLP2 & 71 & 130 & 139 & $4.88 \times 10^{-29}$ & $9.07 \times 10^{-27}$ \\
  \rowcolor{black!10} 
  C10orf10 & 73 & 130 & 138 & $6.72 \times 10^{-29}$ & $1.20 \times 10^{-26}$ \\
  \rowcolor{black!5} 
  DULLARD & 74 & 131 & 138 & $9.29 \times 10^{-29}$ & $1.61 \times 10^{-26}$ \\
  \rowcolor{black!10} 
  PPM1F & 64 & 130 & 136 & $1.61 \times 10^{-28}$ & $2.65 \times 10^{-26}$ \\
  \rowcolor{black!5} 
  OBFC2A & 69 & 130 & 136 & $2.49 \times 10^{-28}$ & $3.93 \times 10^{-26}$ \\
  \rowcolor{black!10} 
  RPL11 & 70 & 130 & 136 & $2.56 \times 10^{-28}$ & $3.97 \times 10^{-26}$ \\
  \rowcolor{black!5} 
  RPL18A & 70 & 130 & 135 & $3.08 \times 10^{-28}$ & $4.70 \times 10^{-26}$ \\
  \rowcolor{black!10} 
  MFNG & 76 & 131 & 133 & $7.73 \times 10^{-28}$ & $1.12 \times 10^{-25}$ \\
  \rowcolor{black!5} 
  RPS17 & 77 & 131 & 133 & $8.94 \times 10^{-28}$ & $1.29 \times 10^{-25}$ \\
  \rowcolor{black!10} 
  MGAT1 & 73 & 130 & 132 & $1.44 \times 10^{-27}$ & $2.03 \times 10^{-25}$ \\
  \rowcolor{black!5} 
  RPS12 & 72 & 130 & 128 & $8.57 \times 10^{-27}$ & $1.12 \times 10^{-24}$ \\
  \rowcolor{black!10} 
  C10orf54 & 73 & 130 & 127 & $1.37 \times 10^{-26}$ & $1.75 \times 10^{-24}$ \\
  \rowcolor{black!5} 
  LOC286367 & 72 & 130 & 126 & $2.20 \times 10^{-26}$ & $2.70 \times 10^{-24}$ \\
  \rowcolor{black!10} 
  GMFG & 70 & 130 & 126 & $2.20 \times 10^{-26}$ & $2.70 \times 10^{-24}$ \\ 
  \hline
\end{tabular}
\begin{tablenotes}
\raggedright \small
Strongest candidate SL partners for \textit{CDH1} by \gls{SLIPT} with observed and expected numbers of \gls{TCGA} breast cancer samples with low expression of both genes.
\end{tablenotes}
\end{threeparttable}
}
\end{table*}

The modified mtSLIPT methodology (as described in Section~\ref{methods:SLIPT}) was also applied to the normalised TCGA breast cancer gene expression dataset, against somatic loss of function mutations in \textit{CDH1}. As shown in Table~\ref{tab:gene_mtSL}, the most significant genes also had strong evidence of expression associated with \textit{CDH1} mutations (high $\chi^2$ values) with fewer samples with \textit{CDH1} exhibiting low expression each candidate gene than expected statistically. These genes were not a strongly supported as the expression analysis (in Table~\ref{tab:gene_SL}), however, nor were as many genes detected. This is perhaps unsurprising due to the lower sample size with matching somatic mutation data and the lower frequency of \textit{CDH1} mutations compared to low expression defined by $\sfrac{1}{3}$ quantiles.

The mtSLIPT candidates had more genes involved in cell and gene regulation, particularly DNA and RNA binding factors. The strongest candidates also included microtubule (\textit{KIF12}), microfibril (\textit{MFAP4}), and cell adhesion (\textit{TENC1}) genes consistent with the established cytoskeletal role of \textit{CDH1}. The elastin gene (\textit{ELN}) was notably strongly supported by both expression and mutation SLIPT analysis of \text{CDH1} supporting a interactions with extracellular proteins and the tumour microenvironment.

%%appendix
%\label{tab:gene_mtSL}

\subsection{Synthetic Lethal Pathways in Breast Cancer} \label{chapt3:exprSL_pathways}

Translational pathways were strongly over-represented in \gls{SLIPT} partners, as shown in Table~\ref{tab:pathway_exprSL}. These include ribosomal subunits, initiation, peptide elongation, and termination. Regulatory processes involving mRNA including 3' untranslated region (UTR) binding, L13a-mediated translational silencing, and nonsense-mediated decay were also implicated. These are consistent with protein translation being subject to ``non-oncogene addiction'' \citep{Luo2009}, as a core process that is dysregulated to sustain cancer proliferation and survival \citep{Gao2015}.

Immune pathways, including the adaptive immune system and responses to infectious diseases were also strongly implicated as synthetic lethal with loss of E-cadherin. This is consistent with the alterations of immune response being a hallmark of cancer \cite{Hanahan2000}, since evading the immune system is necessary for cancer survival. Either of these systems are potential means to target \textit{CDH1} deficient cells, although these were not detected in an isolated cell line experimental screen \citep{Telford2015} and the differences between the findings in patient data are described in more detail in Section~\ref{chapt3:compare_pathway}.

\begin{table*}[!ht]
\caption{Pathways for \textit{CDH1} partners from SLIPT}
\label{tab:pathway_exprSL}
\centering
\resizebox{1 \textwidth}{!}{
\begin{threeparttable}
\begin{tabular}{lccc}
  \cellcolor{white} \textbf{Pathways Over-represented} & \textbf{Pathway Size} & \textbf{SL Genes} & \textbf{p-value (FDR)} \\
  \hline
  \rowcolor{black!10}
  Eukaryotic Translation Elongation &  86 &  81 & $1.3 \times 10^{-207}$ \\ 
  \rowcolor{black!5}
  Peptide chain elongation &  83 &  78 & $5.6 \times 10^{-201}$ \\ 
  \rowcolor{black!10}
  Eukaryotic Translation Termination &  83 &  77 & $1.2 \times 10^{-196}$ \\ 
  \rowcolor{black!5}
  Viral mRNA Translation &  81 &  76 & $1.2 \times 10^{-196}$ \\ 
  \rowcolor{black!10}
  Formation of a pool of free 40S subunits &  93 &  81 & $3.7 \times 10^{-194}$ \\ 
  \rowcolor{black!5}
  Nonsense Mediated Decay independent of the Exon Junction Complex &  88 &  77 & $5.3 \times 10^{-187}$ \\ 
  \rowcolor{black!10}
  L13a-mediated translational silencing of Ceruloplasmin expression & 103 &  82 & $9.6 \times 10^{-183}$ \\ 
  \rowcolor{black!5}
  3' -UTR-mediated translational regulation & 103 &  82 & $9.6 \times 10^{-183}$ \\ 
  \rowcolor{black!10}
  GTP hydrolysis and joining of the 60S ribosomal subunit & 104 &  82 & $1.9 \times 10^{-181}$ \\ 
  \rowcolor{black!5}
  Nonsense-Mediated Decay & 103 &  80 & $6.2 \times 10^{-176}$ \\ 
  \rowcolor{black!10}
  Nonsense Mediated Decay enhanced by the Exon Junction Complex & 103 &  80 & $6.2 \times 10^{-176}$ \\ 
  \rowcolor{black!5}
  Adaptive Immune System & 412 & 167 & $6.5 \times 10^{-174}$ \\ 
  \rowcolor{black!10}
  Eukaryotic Translation Initiation & 111 &  82 & $5.7 \times 10^{-173}$ \\ 
  \rowcolor{black!5}
  Cap-dependent Translation Initiation & 111 &  82 & $5.7 \times 10^{-173}$ \\ 
  \rowcolor{black!10}
  SRP-dependent cotranslational protein targeting to membrane & 104 &  79 & $2.0 \times 10^{-171}$ \\ 
  \rowcolor{black!5}
  Translation & 141 &  91 & $6.1 \times 10^{-170}$ \\ 
  \rowcolor{black!10}
  Infectious disease & 347 & 146 & $1.6 \times 10^{-166}$ \\ 
  \rowcolor{black!5}
  Influenza Infection & 117 &  81 & $1.9 \times 10^{-163}$ \\ 
  \rowcolor{black!10}
  Influenza Viral RNA Transcription and Replication & 108 &  77 & $1.9 \times 10^{-160}$ \\ 
  \rowcolor{black!5}
  Influenza Life Cycle & 112 &  77 & $2.5 \times 10^{-156}$ \\ 
   \hline
\end{tabular}
\begin{tablenotes}
\raggedright \small
Gene set over-representation analysis (hypergeometric test) for Reactome pathways in \gls{SLIPT} partners for \textit{CDH1}.
\end{tablenotes}
\end{threeparttable}
}
\end{table*}

It is also notable that the pathways over-represented in \gls{SLIPT} candidate genes have strongly significant over-representation of Reactome pathways from the hypergeometric test (as described in Section~\ref{methods:enrichment}). Even after adjusting stringently for multiple tests, biologically related pathways were supported together. These pathways are further supported by testing for synthetic lethality against \textit{CDH1} mutations (mtSLIPT) with many of these pathways also among the most strongly supported in this analysis (shown in Table~\ref{tab:pathway_mtSL}). This mutation-based analysis more closely represents the null \textit{CDH1} mutations in HDGC \citep{Guilford1998} and the experimental MCF10A cell model \citep{Chen2014}. There was still support for translational and immune pathways not detected in the isolated experimental system.  G-protein-coupled receptors (GPCRs) also among the most strongly supported pathways, supporting the experimental findings of \citet{Telford2015} for these intracellular signalling pathways already being targeted for other diseases. 

%%appendix
%\label{tab:pathway_mtSL}

\FloatBarrier


\subsection{Expression Profiles of Synthetic Lethal Partners} \label{chapt3:exprSL_clusters}

Due to the sheer number of gene candidates, investigations proceeded into correlation structure and pathway over-represent\-ation. These analyses also examined expression patterns of synthetic lethal gene candidates. This serves to explore the functional similarity of the synthetic lethal partners of \textit{CDH1}, with the eventual aim to assess their utility as drug targets. As shown in Figure~\ref{fig:slipt_expr} (which clusters \textit{CDH1} lowly expressing samples separately), there were several large clusters of genes among the  expression profiles of the \textit{CDH1} synthetic lethal candidate partners. The clustering suggests co-regulation of genes or pathway correlation between partner gene candidates. A number of candidates from an experimental RNAi screen study performed by \citet{Telford2015} were also identified by this approach. In addition, we identified novel gene candidates, which had not been observed affect viability in isogenic cell line experiments. %or in some cases, even opposite effects of selective cell death or toxicity to both isogenic cell lines.

\begin{figure*}[!ht]
%\begin{mdframed}
  \centering
  \resizebox{0.99 \textwidth}{!}{
    \includegraphics{CDH1_Heatmaps_Genes_Split_By_CDH1_z-trans_exprSL_cordistx_Pub.png}
   }
    \caption[Synthetic lethal expression profiles of analysed samples]{\small \textbf{Synthetic lethal expression profiles of analysed samples.} Gene expression profile heatmap (correlation distance, complete linkage) of all samples (separated by the $\sfrac{1}{3}$ quantile of \textit{CDH1} expression) analysed in TCGA breast cancer dataset for gene expression of 5,165 candidate partners of E-cadherin (\textit{CDH1}) from \gls{SLIPT} prediction (with FDR adjusted $p < 0.05$). Deeply clustered, inter-correlated genes form several main groups, each containing genes that were SL candidates or lethal in an \gls{siRNA} screen \citep{Telford2015}. Screen results for synthetic lethal (SL), the reverse effect (RSL), or lethal cell viability are shown as reported by \citet{Telford2015}. Clusters had different sample groups highly expressing the synthetic lethal candidates in \textit{CDH1} low samples, notably `normal-like', `basal-like', and estrogen receptor negative samples have elevated expression in one or more distinct clusters showing complexity and variation among candidate synthetic lethal partners. \textit{CDH1} low samples also contained most of samples with \textit{CDH1} mutations (shown in black). Negative values for mutation and screen data are shown in light grey with missing data in white.
   %This suggests that multiple targets may be needed to target \textit{CDH1} deficiency across genetic backgrounds and that combination therapy may be more effective. 
}
\label{fig:slipt_expr}
%\end{mdframed}
\end{figure*}

In these expression profiles, a gene with a moderate or high signal across samples exhibiting low \textit{CDH1} expression would represent a potential drug target. However, it appears that several molecular subtypes of cancer have elevation of different clusters of synthetic lethal candidates in samples with low \textit{CDH1}. This clustering suggests that different targets (or combinations) could be effective in different patients, suggesting potential utility for stratification.  In particular, estrogen receptor negative, basal-like subtype, and ``normal-like'' tumours \citep{Eroles2012, Parker2009, Dai2015} have elevation of genes specific to particular clusters, indicative of some synthetic lethal interactions being specific to a particular molecular subtype or genetic background. Thus synthetic lethal drug therapy against these subtypes may be ineffective if it were designed against genes in another cluster.
 
A similar correlation structure was observed among the candidates tested against \textit{CDH1} mutation (mtSLIPT), as shown in Figure~\ref{fig:slipt_expr_mtSL}. This clustering analysis similarly identified several major clusters of putative synthetic lethal partner genes. In this case, many partner genes had consistently high expression across most of the (predominantly lobular subtype) \textit{CDH1} breast cancer samples. However, a major exception to this in the \textit{CDH1} expression analysis were the normal samples which were excluded from the mutation data (as they were not tested for tumour-specific genotypes). This supports synthetic lethal interventions being more applicable to \textit{CDH1} mutant tumours. There was still considerable correlation structure, particularly among \textit{CDH1} wildtype samples, sufficient to distinguish gene clusters. In contrast to the expression analysis the (predominantly ductal \textit{CDH1} wildtype) basal-like subtype and estrogen receptor negative samples had depleted expression among most candidate synthetic lethal partners. This is consistent with synthetic lethal interventions only being effective in lobular estrogen receptor positive breast cancers in which they are a more common, as recurrent (driver) mutation. However, the remaining samples are still informative for synthetic lethal analysis (by \gls{SLIPT}) as it requires highly expressing \textit{CDH1} samples for comparison.

\FloatBarrier

The \textit{CDH1} mutant samples (in Figure~\ref{fig:slipt_expr}) were predominantly among the low \textit{CDH1} expressing samples and distributed throughout \textit{CDH1} samples with clustering analysis. Thus the molecular profiles of \textit{CDH1} low samples were indistinguishable from \textit{CDH1} mutant samples, with the exception of normal samples (that do not have somatic mutation data available). Conversely, many of the \textit{CDH1} mutant samples (in Figure~\ref{fig:slipt_expr_mtSL}) had among the lowest \textit{CDH1} expression, and some of the synthetic lethal partners were also highly expressed in low expressing \textit{CDH1} wildtype samples, despite these not being considered as ``inactivated'' by mtSLIPT analysis.

Together these results support the use of low \textit{CDH1} expression as a strategy for detecting \textit{CDH1} inactivation. This has the benefit of increasing sample size (including samples such as normal tissue which do not have somatic mutation data available) and increasing the expected number of mutually inactive (low-low) samples for the directional criteria of (mt)SLIPT which enabling it to better distinguish significant deviations below this (as discussed in Section~\ref{chapt5:compare_methods}). This also circumvents the assumption that all (detected) mutations are inactivating (although synonymous mutations were excluded from the analysis), which may not be the case for several highly expressing \textit{CDH1} mutant samples that do not cluster together in Figures~\ref{fig:slipt_expr} or~\ref{fig:slipt_expr_mtSL}. One of these exhibits among the lowest expression for many predicted synthetic lethal partners and would not be vulnerable to inactivation of these genes. As such correctly genotyping inactivating mutations will be essential in clinical practice for synthetic lethal targeting tumour suppressor genes, particularly for other genes such as \textit{TP53} where oncogenic and tumour suppressor mutations (with different molecular consequences) are both common in cancers. Using expression as a measure of gene expression also avoids the assumptions that mutations are somatic rather than germline and that gene inactivation is by detectable mutations rather than other mechanisms such as epigenetic changes which is supported by many lowly expressing \textit{CDH1} wildtype samples clustering with similar profiles to mutant samples.

%%appendix
%\label{fig:slipt_expr_mtSL}

%Figure 3.   Heatmap of RNASeq gene expression in predicted SL partners of \textit{CDH1} showing distinct subgroups of SL partners and links between SL partner expression and clinical variables.

\FloatBarrier

\subsubsection{Subgroup Pathway Analysis}

%Table 5.  Gene set enrichment results for subgroups of \textit{CDH1} SL partners shows functional variation.


\begin{table*}[!hp]
\caption{Pathway composition for clusters of \textit{CDH1} partners from SLIPT}
\label{tab:pathway_clusters}
\centering
%\begin{tiny}
%\makebox[\textwidth][c]{
\resizebox{0.75 \textwidth}{!}{
\begin{threeparttable}
\begin{tabular}{lccc}
%\caption{Pathway composition for clusters of \textit{CDH1} partners from SLIPT}
%\label{tab:pathway_clusters}
  \large{\textbf{Pathways Over-represented in Cluster 1}} & \large{\textbf{Pathway Size}} & \large{\textbf{Cluster Genes}} & \large{\textbf{p-value (FDR)}} \\ %(833 genes)  
  \hline
  \rowcolor{Cluster_Blue!20}
  Collagen formation &  67 &  10 & $4.0 \times 10^{-11}$ \\
  \rowcolor{Cluster_Blue!15} 
  Extracellular matrix organisation & 238 &  21 & $1.8 \times 10^{-9}$ \\
  \rowcolor{Cluster_Blue!20} 
  Collagen biosynthesis and modifying enzymes &  56 &   8 & $1.8 \times 10^{-9}$ \\
  \rowcolor{Cluster_Blue!15} 
  Uptake and actions of bacterial toxins &  22 &   5 & $9.5 \times 10^{-9}$ \\
  \rowcolor{Cluster_Blue!20} 
  Elastic fibre formation &  37 &   6 & $1.9 \times 10^{-8}$ \\
  \rowcolor{Cluster_Blue!15} 
  Muscle contraction &  62 &   7 & $2.4 \times 10^{-7}$ \\
  \rowcolor{Cluster_Blue!20} 
  Fatty acid, triacylglycerol, and ketone body metabolism & 117 &  10 & $4.9 \times 10^{-7}$ \\
  \rowcolor{Cluster_Blue!15} 
  XBP1(S) activates chaperone genes &  51 &   6 & $6.6 \times 10^{-7}$ \\
  \rowcolor{Cluster_Blue!20} 
  IRE1alpha activates chaperones &  54 &   6 & $1.2 \times 10^{-6}$ \\
  \rowcolor{Cluster_Blue!15} 
  Neurotoxicity of clostridium toxins &  10 &   3 & $1.3 \times 10^{-6}$ \\
  \rowcolor{Cluster_Blue!20} 
  Retrograde neurotrophin signalling &  10 &   3 & $1.3 \times 10^{-6}$ \\
  \rowcolor{Cluster_Blue!15} 
  Assembly of collagen fibrils and other multimeric structures &  40 &   5 & $1.9 \times 10^{-6}$ \\
  \rowcolor{Cluster_Blue!20} 
  Collagen degradation &  58 &   6 & $2.0 \times 10^{-6}$ \\
  \rowcolor{Cluster_Blue!15} 
  Arachidonic acid metabolism &  41 &   5 & $2.1 \times 10^{-6}$ \\
  \rowcolor{Cluster_Blue!20} 
  Synthesis of PA &  26 &   4 & $3.0 \times 10^{-6}$ \\
  \rowcolor{Cluster_Blue!15} 
  Signalling by NOTCH &  80 &   7 & $3.3 \times 10^{-6}$ \\
  \rowcolor{Cluster_Blue!20} 
  Signalling to RAS &  27 &   4 & $3.7 \times 10^{-6}$ \\
  \rowcolor{Cluster_Blue!15} 
  Integrin cell surface interactions &  82 &   7 & $4.2 \times 10^{-6}$ \\
%  \rowcolor{Cluster_Blue!20} 
%  Smooth Muscle Contraction &  28 &   4 & $4.4 \times 10^{-6}$ \\
%  \rowcolor{Cluster_Blue!15} 
%  ECM proteoglycans &  66 &   6 & $6.3 \times 10^{-6}$ \\ 
  \hline
  %\\
  \cellcolor{white} \large{\textbf{Pathways Over-represented in Cluster 2}} & \large{\textbf{Pathway Size}} & \large{\textbf{Cluster Genes}} & \large{\textbf{p-value (FDR)}} \\ %(833 genes)  
  \hline
  \rowcolor{Cluster_Green!20}
  Eukaryotic Translation Elongation &  86 &  75 & $1.1 \times 10^{-181}$ \\
  \rowcolor{Cluster_Green!15} 
  Viral mRNA Translation &  81 &  72 & $9.8 \times 10^{-179}$ \\
  \rowcolor{Cluster_Green!20} 
  Peptide chain elongation &  83 &  72 & $1.9 \times 10^{-175}$ \\
  \rowcolor{Cluster_Green!15} 
  Eukaryotic Translation Termination &  83 &  72 & $1.9 \times 10^{-175}$ \\
  \rowcolor{Cluster_Green!20} 
  Formation of a pool of free 40S subunits &  93 &  75 & $1.9 \times 10^{-171}$ \\
  \rowcolor{Cluster_Green!15} 
  Nonsense Mediated Decay independent of the Exon Junction Complex &  88 &  72 & $9.9 \times 10^{-168}$ \\
  \rowcolor{Cluster_Green!20} 
  L13a-mediated translational silencing of Ceruloplasmin expression & 103 &  75 & $3.0 \times 10^{-159}$ \\
  \rowcolor{Cluster_Green!15} 
  3' -UTR-mediated translational regulation & 103 &  75 & $3.0 \times 10^{-159}$ \\
  \rowcolor{Cluster_Green!20} 
  Nonsense-Mediated Decay & 103 &  75 & $3.0 \times 10^{-159}$ \\
  \rowcolor{Cluster_Green!15} 
  Nonsense Mediated Decay enhanced by the Exon Junction Complex & 103 &  75 & $3.0 \times 10^{-159}$ \\
  \rowcolor{Cluster_Green!20} 
  SRP-dependent cotranslational protein targeting to membrane & 104 &  75 & $3.2 \times 10^{-158}$ \\
  \rowcolor{Cluster_Green!15} 
  GTP hydrolysis and joining of the 60S ribosomal subunit & 104 &  75 & $3.2 \times 10^{-158}$ \\
  \rowcolor{Cluster_Green!20} 
  Eukaryotic Translation Initiation & 111 &  75 & $4.5 \times 10^{-151}$ \\
  \rowcolor{Cluster_Green!15} 
  Cap-dependent Translation Initiation & 111 &  75 & $4.5 \times 10^{-151}$ \\
  \rowcolor{Cluster_Green!20} 
  Influenza Infection & 117 &  75 & $1.4 \times 10^{-145}$ \\
  \rowcolor{Cluster_Green!15} 
  Influenza Viral RNA Transcription and Replication & 108 &  72 & $5.7 \times 10^{-145}$ \\
  \rowcolor{Cluster_Green!20} 
  Translation & 141 &  81 & $8.0 \times 10^{-143}$ \\
  \rowcolor{Cluster_Green!15} 
  Influenza Life Cycle & 112 &  72 & $2.3 \times 10^{-141}$ \\
%  \rowcolor{Cluster_Green!20} 
%  Infectious disease & 347 & 103 & $2.2 \times 10^{-95}$ \\
%  \rowcolor{Cluster_Green!15} 
%  Formation of the ternary complex, and subsequently, the 43S complex &  47 &  33 & $6.8 \times 10^{-80}$ \\
  \hline
  %\\
  \cellcolor{white} \large{\textbf{Pathways Over-represented in Cluster 3}} & \large{\textbf{Pathway Size}} & \large{\textbf{Cluster Genes}} & \large{\textbf{p-value (FDR)}} \\ %(833 genes)  
  \hline
  \rowcolor{Cluster_Orange!30}
  Adaptive Immune System & 412 &  90 & $6.1 \times 10^{-61}$ \\
  \rowcolor{Cluster_Orange!20} 
  Chemokine receptors bind chemokines &  52 &  27 & $6.7 \times 10^{-56}$ \\
  \rowcolor{Cluster_Orange!30} 
  Generation of second messenger molecules &  29 &  21 & $6.5 \times 10^{-55}$ \\
  \rowcolor{Cluster_Orange!20} 
  Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell &  64 &  29 & $6.5 \times 10^{-55}$ \\
  \rowcolor{Cluster_Orange!30} 
  TCR signalling &  62 &  27 & $8.9 \times 10^{-51}$ \\
  \rowcolor{Cluster_Orange!20} 
  Peptide ligand-binding receptors & 161 &  40 & $1.5 \times 10^{-45}$ \\
  \rowcolor{Cluster_Orange!30} 
  Translocation of ZAP-70 to Immunological synapse &  16 &  14 & $3.1 \times 10^{-43}$ \\
  \rowcolor{Cluster_Orange!20} 
  Costimulation by the CD28 family &  51 &  22 & $4.0 \times 10^{-43}$ \\
  \rowcolor{Cluster_Orange!30} 
  PD-1 signalling &  21 &  15 & $4.0 \times 10^{-41}$ \\
  \rowcolor{Cluster_Orange!20} 
  Class A/1 (Rhodopsin-like receptors) & 258 &  50 & $6.7 \times 10^{-41}$ \\
  \rowcolor{Cluster_Orange!30} 
  Phosphorylation of CD3 and TCR zeta chains &  18 &  14 & $1.3 \times 10^{-40}$ \\
  \rowcolor{Cluster_Orange!20} 
  Interferon gamma signalling &  74 &  24 & $5.0 \times 10^{-39}$ \\
  \rowcolor{Cluster_Orange!30} 
  GPCR ligand binding & 326 &  57 & $1.8 \times 10^{-38}$ \\
  \rowcolor{Cluster_Orange!20} 
  Cytokine Signalling in Immune system & 268 &  48 & $8.9 \times 10^{-37}$ \\
  \rowcolor{Cluster_Orange!30} 
  Downstream TCR signalling &  45 &  18 & $1.8 \times 10^{-35}$ \\
  \rowcolor{Cluster_Orange!20} 
  G$_{\alpha i}$ signalling events & 167 &  33 & $2.2 \times 10^{-33}$ \\
  \rowcolor{Cluster_Orange!30} 
  Cell surface interactions at the vascular wall &  99 &  21 & $1.3 \times 10^{-26}$ \\
  \rowcolor{Cluster_Orange!20} 
  Interferon Signalling & 164 &  28 & $1.7 \times 10^{-26}$ \\
%  \rowcolor{Cluster_Orange!30} 
%  Extracellular matrix organisation & 238 &  35 & $2.7 \times 10^{-25}$ \\
%  \rowcolor{Cluster_Orange!20} 
%  Antigen activates B Cell Receptor leading to generation of second messengers &  32 &  12 & $7.2 \times 10^{-25}$ \\
   \hline
  %\\ 
  \cellcolor{white} \large{\textbf{Pathways Over-represented in Cluster 4}} & \large{\textbf{Pathway Size}} & \large{\textbf{Cluster Genes}} & \large{\textbf{p-value (FDR)}} \\ %(833 genes)  
  \hline 
  \rowcolor{Cluster_Red!20}
  Extracellular matrix organisation & 238 &  48 & $8.0 \times 10^{-41}$ \\
  \rowcolor{Cluster_Red!15} 
  Class A/1 (Rhodopsin-like receptors) & 258 &  47 & $2.8 \times 10^{-36}$ \\
  \rowcolor{Cluster_Red!20} 
  GPCR ligand binding & 326 &  54 & $2.1 \times 10^{-34}$ \\
  \rowcolor{Cluster_Red!15} 
  G$_{\alpha s}$ signalling events &  83 &  22 & $1.4 \times 10^{-31}$ \\
  \rowcolor{Cluster_Red!20} 
  GPCR downstream signalling & 472 &  68 & $1.1 \times 10^{-29}$ \\
  \rowcolor{Cluster_Red!15} 
  Haemostasis & 423 &  61 & $3.3 \times 10^{-29}$ \\
  \rowcolor{Cluster_Red!20} 
  Platelet activation, signalling and aggregation & 180 &  31 & $7.1 \times 10^{-28}$ \\
  \rowcolor{Cluster_Red!15} 
  Binding and Uptake of Ligands by Scavenger Receptors &  40 &  14 & $9.9 \times 10^{-27}$ \\
  \rowcolor{Cluster_Red!20} 
  RA biosynthesis pathway &  22 &  11 & $2.5 \times 10^{-26}$ \\
  \rowcolor{Cluster_Red!15} 
  Response to elevated platelet cytosolic Ca$^{2+}$ &  82 &  19 & $3.0 \times 10^{-26}$ \\
  \rowcolor{Cluster_Red!20} 
  Developmental Biology & 420 &  57 & $3.5 \times 10^{-26}$ \\
  \rowcolor{Cluster_Red!15} 
  G$_{\alpha i}$ signalling events & 167 &  28 & $7.3 \times 10^{-26}$ \\
  \rowcolor{Cluster_Red!20} 
  Platelet degranulation &  77 &  18 & $1.6 \times 10^{-25}$ \\
  \rowcolor{Cluster_Red!15} 
  Gastrin-CREB signalling pathway via PKC and MAPK & 171 &  28 & $2.5 \times 10^{-25}$ \\
  \rowcolor{Cluster_Red!20} 
  Muscle contraction &  62 &  16 & $4.7 \times 10^{-25}$ \\
  \rowcolor{Cluster_Red!15} 
  G$_{\alpha q}$ signalling events & 150 &  25 & $3.2 \times 10^{-24}$ \\
  \rowcolor{Cluster_Red!20} 
  Retinoid metabolism and transport &  34 &  12 & $5.0 \times 10^{-24}$ \\
  \rowcolor{Cluster_Red!15} 
  Phase 1 - Functionalisation of compounds &  67 &  16 & $6.5 \times 10^{-24}$ \\
%  \rowcolor{Cluster_Red!20} 
%  Signalling by Retinoic Acid &  42 &  13 & $6.7 \times 10^{-24}$ \\
%  \rowcolor{Cluster_Red!15} 
%  Degradation of the extracellular matrix & 102 &  19 & $1.4 \times 10^{-22}$ \\ 
  \hline
\end{tabular}
\begin{tablenotes}
\raggedright %\small
Pathway over-representation analysis for Reactome pathways with the number of genes in each pathway (Pathway Size), number of genes within the pathway identified (Cluster Genes), and the pathway over-representation p-value (adjusted by FDR) from the hypergeometric test.  
\end{tablenotes}
\end{threeparttable}
}
\end{table*}

%%committee
Synthetic lethal gene candidates for \textit{CDH1} from \gls{SLIPT} analysis of RNA-Seq gene expression data were also used for pathway over-representation analyses (as described in Section~\ref{methods:enrichment}). The correlation structure in the expression of candidates synthetic lethal genes in \textit{CDH1} low tumours (lowest $\sfrac{1}{3}$\textsuperscript{rd} quantile of expression) was examined for distinct biological pathways in subgroups of genes elevated in different clusters of samples. These genes were highly expressed in different samples with their clinical factors including estrogen receptor status and intrinsic subtype, from the \gls{PAM50} procedure \citep{Parker2009} shown in Figure~\ref{fig:slipt_expr}.

%%paper
As shown by the most over-represented pathways in Table~\ref{tab:pathway_clusters}, each correlated cluster of candidate synthetic lethal partners of \textit{CDH1} contains functionally different genes. %Each correlated subgroup of synthetic lethal candidate genes has markedly different biological functions.
Cluster 1 contains genes with less evidence of over-represented pathways than other clusters, corresponding to less correlation between genes within the cluster, and to it being a relatively small group. While there is some indication that collagen biosynthesis, microfibril elastic fibres, extracellular matrix, and metabolic pathways may be over-represent\-ed in Cluster 1, these results are mainly based on small pathways containing few synthetic lethal genes. Genes in Cluster 2 exhibited low expression in normal tissue samples compared to tumour samples (see Figure~\ref{fig:slipt_expr}) and show compelling evidence of over-represent\-ation of post-transcriptional gene regulation and protein translation processes. Similarly, Cluster 3 has over-represent\-ation of immune signalling pathways (including chemokines, secondary messenger, and TCR signalling) and downstream intracellular signalling cascades such as G protein coupled receptor (GPCR) and  G$_{\alpha i}$ signalling events. While pathway over-represent\-ation was weaker among genes in Cluster 4, they contained intracellular signalling pathways and were highly expressed in normal samples (in contrast to Cluster 2). Cluster 4 also involved extracellular factors and stimuli such as extracellular matrix, platelet activation, ligand receptors, and retinoic acid signalling.

Based on these results, potential synthetic lethal partners of \textit{CDH1} include processes known to be dysregulated in cancer, such as translational, cytoskeletal, and immune processes. Intracellular signalling cascades such as the GPCRs and extracellular stimuli for these pathways were also implicated in potential synthetic lethality with \textit{CDH1}.

Similar translational, cytoskeletal, and immune processes were identified among \gls{SLIPT} partners with respect to \textit{CDH1} mutation, shown in Table~\ref{tab:pathway_clusters_mtSL}. While GPCR signalling was replicated in mtSLIPT analysis, there was also stronger over-representation for NOTCH, ERBB2, and PI3K/AKT signalling in mutation analysis consistent with these signals being important for proliferation of \textit{CDH1} deficient tumours. The GCPR and PI3K/AKT pathways are of particular interest as pathways with oncogenic mutations that can be targeted and downstream effects on translation (a strongly supported process across analyses). Extracellular matrix pathways (e.g., elastic fibre formation) were also supported across analyses (in Tables~\ref{tab:pathway_clusters} and~\ref{tab:pathway_clusters_mtSL}) consistent with the established cell-cell signalling role of \textit{CDH1} and the importance of the tumour microenvironment for cancer proliferation.

%%appendix
%\label{tab:pathway_clusters_mtSL}


\FloatBarrier

\section{Comparing Synthetic Lethal Gene Candidates} \label{chapt3:compare_SL_genes}  

%\subsection{Comparison with differential expression} \label{chapt3:compare_differential_expression}

%A transcriptome experiment has been conducted by the Cancer Genetics Laboratory to test their \textit{CDH1}$^{-/-}$ null MCF10A cell lines compared to an otherwise isogenic wildtype \citep{Chen2014}. While differential expression analysis was inconclusive due to few technical replicates, this data was also useful to determine genes which were not detectable in MCF10A cell lines which would not be expected to detect synthetic lethality in \gls{siRNA} screen data even if they were predicted to be synthetic lethal in expression data. 

\subsection{Primary siRNA Screen Candidates} \label{chapt3:primary_screen}

Gene candidates were compared between computational (\gls{SLIPT} in TCGA breast cancer data) and experimental (the primary \gls{siRNA} screen performed by \citet{Telford2015}) approaches in Figure~\ref{fig:Venn_allgenes}. The number of genes detected by both methods did not produce a significant overlap but these may be difficult to compare due to vast differences between the detection methods. There were similar issues in the comparison of mtSLIPT genes tested against \textit{CDH1} mutations (in Appendix Figure~\ref{fig:Venn_allgenes_stad_mtSL}), despite excluding genes not tested by both methods in either test. However, these intersecting genes may still be functionally informative or amenable to drug triage as they were replicated across both methods and pathway over-represent\-ation differed between the sections of the Venn diagram (see Figure~\ref{fig:Venn_allgenes}).

\begin{figure}[!ht]
%\begin{mdframed}
  \centering
  \resizebox{0.66 \columnwidth}{!}{
    \includegraphics{Venn_exprSL_siRNA_allgenes_reduced_Pub.png}
   }
    \caption[Comparison of SLIPT to siRNA]{\small \textbf{Comparison of \gls{SLIPT} to \gls{siRNA}.} Testing the overlap of gene candidates for E-cadherin synthetic lethal partners between computational (\gls{SLIPT}) and experimental screening (\gls{siRNA}) approaches. The $\chi^2$ test suggests that the overlap is no more than would be expected by chance ($p = 0.281$).  Only genes tested by both methods were included. %A Venn diagram of all 16298 genes tested by both approaches.
}
\label{fig:Venn_allgenes}
%\end{mdframed}
\end{figure}

%%appendix
%\label{fig:Venn_allgenes_mtSL}

\FloatBarrier

\subsection{Comparison with Correlation} \label{chapt3:compare_correlation} 

Another potential means to triage drug target candidates is by correlation of expression profiles with \textit{CDH1}. Correlation with \textit{CDH1} was compared to \gls{SLIPT} and \gls{siRNA} results in Figure~\ref{fig:compare_points_correlation_SL}. The genes not detected by \gls{SLIPT} (including \gls{siRNA} candidates) had included gene with insignificant \gls{SLIPT} p-values. As expected, these genes were distributed around a correlation of zero and genes with higher correlation with \textit{CDH1} (either direction) were more significant, although there were exceptions to this trend and larger positive correlations than negative correlations. The majority of \gls{SLIPT} candidates had negative correlations, particularly genes detected by both approaches, although these were typically weak correlations and are unlikely to be sufficient to detect such genes on their own. This is supported by simulation results in Section~\ref{chapt5:compare_methods}.

\begin{figure*}[!htp]
%\begin{mdframed}
\begin{center}
  \resizebox{0.75 \textwidth}{!}{
    \includegraphics{exprSLIPT_siRNA_vs_Correlation_with_CDH1_nlp.pdf}
   }
   \end{center}
   \caption[Compare SLIPT and siRNA genes with correlation]{\small \textbf{Compare \gls{SLIPT} and \gls{siRNA} genes with correlation.} The $\chi^2$ p-values for genes tested by \gls{SLIPT} (in TCGA breast cancer) expression analysis were compared against Pearson's correlation of gene expression with \textit{CDH1}. Genes detected by \gls{SLIPT} or \gls{siRNA} are coloured according to the legend. 
}
\label{fig:compare_points_correlation_SL}
%\end{mdframed}
\end{figure*}

There were not strong postive correlations with \textit{CDH1} among \gls{siRNA} candidates, consistent with previous findings that co-expression is not predictive of synthetic lethality \citep{Jerby2014, Lu2015}. Negative correlation may not be indicative of synthetic lethality either as many \gls{siRNA} candidates also had positive correlations. The \gls{SLIPT} methodology has shown to detect genes with both positive and negative correlations, although it does appear to preferentially detect negatively correlated genes to some extent. These findings were replicated with the mtSLIPT approach against \textit{CDH1} mutation (in Figure~\ref{fig:compare_points_correlation_mtSL}), although the range of the $\chi^2$ p-values differ due to lower sample size for mutation analysis.

The apparent tendancy for genes detected by \gls{SLIPT} or \gls{siRNA} to have negative correlations with \textit{CDH1} expression is not due to the smaller number of genes in these groups. The distribution of \textit{CDH1} correlations differed across these gene groups (as shown by Figures~\ref{fig:compare_correlation_SL} and~\ref{fig:compare_correlation_mtSL}), specifically lower in \gls{SLIPT} candidates (as supported by \gls{ANOVA} in Table~\ref{tab:compare_correlation_SL}). However, these are relatively weak correlations and further triage of gene candidates by correlation is not suitable, nor is use of correlation itself to predict synthetic lethal partners in the first place.

\begin{figure*}[!htp]
%\begin{mdframed}
\begin{center}
  \resizebox{0.75 \textwidth}{!}{
    \includegraphics{vioplotx_exprSLIPT_siRNA_vs_CDH1_Correlation_with_CDH1.pdf}
   }
   \end{center}
   \caption[Compare SLIPT and siRNA genes with correlation]{\small \textbf{Compare \gls{SLIPT} and \gls{siRNA} genes with correlation.} Genes detected as candidate synthetic lethal partners by \gls{SLIPT} (in TCGA breast cancer) expression analysis and experimental screening (with \gls{siRNA}) were compared against Pearson's correlation of gene expression with \textit{CDH1}. There were no differences in correlation between gene groups detected by either approach. 
}
\label{fig:compare_correlation_SL}
%\end{mdframed}
\end{figure*}

\begin{table*}[!htb]
\caption{\Gls{ANOVA} for Synthetic Lethality and Correlation with \textit{CDH1}}
\label{tab:compare_correlation_SL}
\noindent\makebox[\textwidth][c]{%               %centering
\resizebox{0.8 \textwidth}{!}{
\begin{threeparttable}
\begin{tabular}{lccccc}
\hline
                 & DF & Sum Squares & Mean Squares & F-value & p-value \\
\hline
\rowcolor{black!10}
siRNA              &     1    &    0.027     &    0.027     &    2.8209    &    0.09306 \\
\rowcolor{black!5}
SLIPT              &     1    &    134.603    &    134.603    &    14115.9824    &    $<$0.0001 \\
\rowcolor{black!10}
siRNA$\times$SLIPT     &     1    &    0.000      &    0.000      &   0.0073     &    0.93212 \\
\hline
\end{tabular}
\begin{tablenotes}
\raggedright \small
Analysis of variance for correlation with \textit{CDH1} against synthetic lethal detection approaches (with an interaction term). Only genes tested by both methods were included in this analysis.
\end{tablenotes}
\end{threeparttable}
}
}
\end{table*} 

\FloatBarrier

\subsection{Comparison with Primary Screen Viability} \label{chapt3:compare_viability}

A similar comparison of \gls{SLIPT} results was made with the viability ratio (of \textit{CDH1} mutant to wildtype) in the primary \gls{siRNA} screen performed by \citet{Telford2015}. The significance and viability thresholds used for \gls{SLIPT} and \gls{siRNA} detection of synthetic lethal candidate partners of \textit{CDH1} are shown in Figure~\ref{fig:compare_points_viability_SL}. However, not all of the genes below the viability  thresholds were necessarily selected to be candidate partners, as additional criteria were used in each case: directional criteria as for \gls{SLIPT} (see Section~\ref{methods:SLIPT}) and minimum wildtype viability for \gls{siRNA} \citep{Telford2015}.

\begin{figure*}[!htp]
%\begin{mdframed}
\begin{center}
  \resizebox{0.75 \textwidth}{!}{
    \includegraphics{exprSLIPT_siRNA_vs_Viability_Ratio_with_CDH1_nlp.pdf}
   }
   \end{center}
   \caption[Compare SLIPT and siRNA genes with viability]{\small \textbf{Compare \gls{SLIPT} and \gls{siRNA} genes with viability.} The $\chi^2$ p-values for genes tested by \gls{SLIPT} (in TCGA breast cancer) expression analysis were compared (on a log-scale) against the viability ratio of \textit{CDH1} mutant and wildtype cells in the primary \gls{siRNA} screen. Genes detected by \gls{SLIPT} or \gls{siRNA} are coloured according to the legend.% with a grey line for $p=0.05$.
}
\label{fig:compare_points_viability_SL}
%\end{mdframed}
\end{figure*}

There does not appear to be a clear relationship between \gls{SLIPT} and \gls{siRNA} candidates. Many genes not detected by both approaches were numerous in Figures~\ref{fig:Venn_allgenes} and~\ref{fig:Venn_allgenes_mtSL}. These genes detected by either are not necessarily near the thresholds for the other. In this respect the \gls{SLIPT} approach with patient data and cell line experiments are independent means to identify synthetic lethal candidates. While genes detected by both approaches were not necessarily more strongly supported by either, the genes with a viability closer to 1 (no synthetic lethal effect) in \gls{siRNA} included those with more significant \gls{SLIPT} p-values whereas more extreme viability ratios tended to be less significant (as shown by Figure~\ref{fig:compare_points_viability_SL}). However, it should be noted that genes with more moderate viability ratios were more common and \gls{SLIPT} was capable (despite adjusting for multiple testing) of detecting significant genes with extreme viability ratios, particularly those considerably lower than 1. 

However, there was not little support for \gls{SLIPT} candidates having considerably different viability ratios (as shown in Figures~\ref{fig:compare_viability_SL} and~\ref{fig:compare_viability_mtSL}). While the viability thresholds used by \citet{Telford2015} to detect synthetic lethal candidates in the primary screen, the genes identified by \gls{SLIPT} had a higher mean viability ratio (by t-text: $t=2.1553$, $p=0.03117$). However, the effect size was small (mean SLIPT$-$ 1.029, mean SLIPT$+$ 1.037)and the vast majority of \gls{SLIPT} candidate genes did not have different viability in the primary screen to genes not identified by \gls{SLIPT}.

\begin{figure*}[!htp]
%\begin{mdframed}
\begin{center}
  \resizebox{0.75 \textwidth}{!}{
    \includegraphics{vioplotx_exprSLIPT_siRNA_vs_Viability_Ratio_with_CDH1.pdf}
   }
   \end{center}
   \caption[Compare SLIPT genes with siRNA viability]{\small \textbf{Compare \gls{SLIPT} genes with \gls{siRNA} viability.} Genes detected as candidate synthetic lethal partners by \gls{SLIPT} (in TCGA breast cancer) expression analysis were compared against the viability ratio of \textit{CDH1} mutant and wildtype cells in the primary \gls{siRNA} screen. There were clear no differences in viability between genes detected by \gls{SLIPT} and those not with the differences being primarily due to viability thresholds being used to detect synthetic lethality by \citet{Telford2015}. 
}
\label{fig:compare_viability_SL}
%\end{mdframed}
\end{figure*}

\FloatBarrier

\subsection{Comparison with Secondary siRNA Screen Validation} 
\label{chapt3:secondary_screen}

However, it should be noted that genes with a lower viability ratio were not necessarily the most strongly supported by experimental screening. The primary screen (with 4 pooled \glspl{siRNA}) has been used for the majority of comparisons in this thesis because the genome-wide panel of target genes screened enables a large number of genes to be compared with \gls{SLIPT} results from gene expression and somatic mutation analysis. A secondary screen was also performed by \citet{Telford2015} on the isogenic MCF10A breast cell lines to validate the individual (i.e., non-pooled) \glspl{siRNA} separately, with the strongest candidates being those exhibiting synthetic lethal viability ratios replicated across independently targeting \glspl{siRNA}. The strongest candidates from a primary screen were subject to a further secondary screen for validation by independent replication with 4 gene knockdowns with different targeting \glspl{siRNA}. This was performed for the top 500 candidates (with the lowest viability ratio) from the primary screen and the 482 of these genes also tested by \gls{SLIPT} in breast cancer.% (and the 486 genes tested by \gls{SLIPT} in stomach cancer).

The secondary screen results show that \gls{SLIPT} candidate genes were more significantly ($p=7.49 \times 10^{-3}$ by Fisher's exact test) more  likely to be validated in the secondary screen and are thus informative of more robust partner genes, in addition to providing support that these interactions are consistent with expression profiles from heterogeneous patient samples across genetic backgrounds. As shown in Table~\ref{tab:secondary_screen}, there is significant %($p=7.49 \times 10^{-3}$ by Fisher's exact test) %$8.67 \times 10^{-3} by \chi^2 (4 df)
association between SLIPT candidates and stronger validations of siRNA candidates. Since there were more SLIPT$-$ genes among those not validated and more SLIPT$+$ genes among those validated with several siRNAs, this supports the use of SLIPT as a synthetic lethal discovery procedure which may augment such screening experiments.

\begin{table*}[!ht]
\caption{Comparing SLIPT genes against secondary siRNA screen in breast cancer}
\label{tab:secondary_screen}
\begin{center}
%\resizebox{\textwidth}{!}{
\begin{tabular}{>{\cellcolor{white}}rrcccccl}
                                                                            &                                                           & \multicolumn{5}{c}{\bfseries Secondary Screen}                                                                                     &                                           \\ \cline{3-7}
\rowcolor{black!10}
                                                                            & \multicolumn{1}{r|}{\cellcolor{white}}                    & 0/4                      & 1/4                      & 2/4                     & 3/4                     & \multicolumn{1}{c|}{4/4} & \cellcolor{white} \textbf{Total}          \\ \cline{2-8} 
\rowcolor{black!5}
\multicolumn{1}{r|}{\cellcolor{white}}                                      & \multicolumn{1}{r|}{Observed}                             & 70                       & 46                       & 31                      & 8                       & \multicolumn{1}{c|}{2}   &  \multicolumn{1}{l|}{}                     \\
\rowcolor{black!10}
\multicolumn{1}{r|}{\cellcolor{white} \multirow{-2}{*}{\bfseries SLIPT$+$}} & \multicolumn{1}{r|}{Expected}                             & 85                       & 44                       & 10                      & 4                       & \multicolumn{1}{c|}{2}   & \multicolumn{1}{l|}{\multirow{-2}{*}{157}}    \\ \cline{2-8} 
\rowcolor{black!5}
\multicolumn{1}{r|}{\cellcolor{white}}                                      & \multicolumn{1}{r|}{Observed}                             & 190                      & 90                       & 31                      & 10                      & \multicolumn{1}{c|}{4}   & \multicolumn{1}{l|}{}                     \\
\rowcolor{black!10}
\multicolumn{1}{r|}{\cellcolor{white}\multirow{-2}{*}{\bfseries SLIPT$-$}}  & \multicolumn{1}{r|}{Expected}                             & 175                      & 91                       & 42                      & 12                      & \multicolumn{1}{c|}{4}   & \multicolumn{1}{l|}{\multirow{-2}{*}{325}} \\ \cline{2-8} 
\rowcolor{black!5}
\cellcolor{white}                                                           & \multicolumn{1}{r|}{\cellcolor{white} \bfseries Total}    & \multicolumn{1}{c}{280} & \multicolumn{1}{c}{136} & \multicolumn{1}{c}{52} & \multicolumn{1}{c}{18} & \multicolumn{1}{c|}{6}   & \multicolumn{1}{l|}{482}                  \\ \cline{3-8} 
\end{tabular} 
%}
\end{center}
\end{table*}

While the individual genes detected by either approach do not necessarily match (and are potentially false-positives), the biological functions important in \textit{CDH1} deficient cancers and potential mechanisms for specific targeting of them can be further supported by pathway analysis of the gene detected by either method. The genes detected by both approaches may therefore be more informative at the pathway level, where it is unlikely for a pathway to be consistently detected by chance. As the \gls{SLIPT} candidates differ from the siRNA candidates (and are more likely to be validated), they can provide additional mechanisms by which \textit{CDH1} deficient cancers proliferate and vulnerabilities that may be exploited against them by using the synthetic lethal pathways.

\FloatBarrier

\subsection{Comparison to Primary Screen at Pathway Level}  \label{chapt3:compare_pathway}

\begin{table*}[!hp]
\caption{Pathway composition for \textit{CDH1} partners from SLIPT and siRNA screening}
\label{tab:Venn_over-representation}
\centering
\resizebox{0.8 \textwidth}{!}{
\begin{tabular}{sl^c^c^c}
\rowstyle{\bfseries}
  Predicted only by \gls{SLIPT} (4025 genes) & Pathway Size & Genes Identified & p-value (FDR) \\ 
  \hline
  \rowcolor{Cluster_Red!20}
  Eukaryotic Translation Elongation &  80 &  75 & $1.5 \times 10^{-182}$ \\
  \rowcolor{Cluster_Red!15} 
  Peptide chain elongation &  77 &  72 & $2.9 \times 10^{-176}$ \\
  \rowcolor{Cluster_Red!20} 
  Viral mRNA Translation &  75 &  70 & $4.9 \times 10^{-172}$ \\
  \rowcolor{Cluster_Red!15} 
  Eukaryotic Translation Termination &  76 &  70 & $5.9 \times 10^{-170}$ \\
  \rowcolor{Cluster_Red!20} 
  Formation of a pool of free 40S subunits &  87 &  74 & $9.5 \times 10^{-166}$ \\
  \rowcolor{Cluster_Red!15} 
  Nonsense Mediated Decay independent of the Exon Junction Complex &  81 &  70 & $1.2 \times 10^{-160}$ \\
  \rowcolor{Cluster_Red!20} 
  L13a-mediated translational silencing of Ceruloplasmin expression &  97 &  75 & $3.8 \times 10^{-155}$ \\
  \rowcolor{Cluster_Red!15} 
  3' -UTR-mediated translational regulation &  97 &  75 & $3.8 \times 10^{-155}$ \\
  \rowcolor{Cluster_Red!20} 
  GTP hydrolysis and joining of the 60S ribosomal subunit &  98 &  75 & $6.0 \times 10^{-154}$ \\
  \rowcolor{Cluster_Red!15} 
  Nonsense-Mediated Decay &  96 &  73 & $5.2 \times 10^{-150}$ \\
  \rowcolor{Cluster_Red!20} 
  Nonsense Mediated Decay enhanced by the Exon Junction Complex &  96 &  73 & $5.2 \times 10^{-150}$ \\
  \rowcolor{Cluster_Red!15} 
  SRP-dependent cotranslational protein targeting to membrane &  97 &  73 & $7.8 \times 10^{-149}$ \\
  \rowcolor{Cluster_Red!20} 
  Eukaryotic Translation Initiation & 105 &  75 & $4.7 \times 10^{-146}$ \\
  \rowcolor{Cluster_Red!15} 
  Cap-dependent Translation Initiation & 105 &  75 & $4.7 \times 10^{-146}$ \\
  \rowcolor{Cluster_Red!20} 
  Translation & 133 &  83 & $4.0 \times 10^{-142}$ \\
  \rowcolor{Cluster_Red!15} 
  Influenza Viral RNA Transcription and Replication & 102 &  71 & $2.9 \times 10^{-137}$ \\
  \rowcolor{Cluster_Red!20} 
  Influenza Infection & 111 &  74 & $3.7 \times 10^{-137}$ \\
  \rowcolor{Cluster_Red!15} 
  Influenza Life Cycle & 106 &  71 & $2.3 \times 10^{-133}$ \\
  \rowcolor{Cluster_Red!20} 
  Infectious disease & 326 & 125 & $4.2 \times 10^{-120}$ \\
  \rowcolor{Cluster_Red!15} 
  Extracellular matrix organisation & 189 &  77 & $5.4 \times 10^{-95}$ \\
  \hline
  \\
  \rowstyle{\bfseries}
  Detected only by siRNA screen (1599 genes) & Pathway Size & Genes Identified & p-value (FDR) \\ 
  \hline
  \rowcolor{Cluster_Blue!20}
  Class A/1 (Rhodopsin-like receptors) & 282 &  44 & $1.3 \times 10^{-27}$ \\
  \rowcolor{Cluster_Blue!15} 
  GPCR ligand binding & 363 &  52 & $5.8 \times 10^{-26}$ \\
  \rowcolor{Cluster_Blue!20} 
  G$_{\alpha q}$ signalling events & 159 &  26 & $6.7 \times 10^{-23}$ \\
  \rowcolor{Cluster_Blue!15} 
  Gastrin-CREB signalling pathway via PKC and MAPK & 180 &  27 & $2.0 \times 10^{-21}$ \\
  \rowcolor{Cluster_Blue!20} 
  G$_{\alpha i}$ signalling events & 184 &  27 & $5.3 \times 10^{-21}$ \\
  \rowcolor{Cluster_Blue!15} 
  Downstream signal transduction & 146 &  23 & $7.6 \times 10^{-21}$ \\
  \rowcolor{Cluster_Blue!20} 
  Signalling by PDGF & 172 &  25 & $4.0 \times 10^{-20}$ \\
  \rowcolor{Cluster_Blue!15} 
  Peptide ligand-binding receptors & 175 &  25 & $8.5 \times 10^{-20}$ \\
  \rowcolor{Cluster_Blue!20} 
  Signalling by ERBB2 & 146 &  22 & $1.3 \times 10^{-19}$ \\
  \rowcolor{Cluster_Blue!15} 
  DAP12 interactions & 159 &  23 & $2.6 \times 10^{-19}$ \\
  \rowcolor{Cluster_Blue!20} 
  DAP12 signalling & 149 &  22 & $2.7 \times 10^{-19}$ \\
  \rowcolor{Cluster_Blue!15} 
  Organelle biogenesis and maintenance & 264 &  33 & $5.5 \times 10^{-19}$ \\
  \rowcolor{Cluster_Blue!20} 
  Signalling by NGF & 266 &  33 & $8.2 \times 10^{-19}$ \\
  \rowcolor{Cluster_Blue!15} 
  Downstream signalling of activated FGFR1 & 134 &  20 & $1.1 \times 10^{-18}$ \\
  \rowcolor{Cluster_Blue!20} 
  Downstream signalling of activated FGFR2 & 134 &  20 & $1.1 \times 10^{-18}$ \\
  \rowcolor{Cluster_Blue!15} 
  Downstream signalling of activated FGFR3 & 134 &  20 & $1.1 \times 10^{-18}$ \\
  \rowcolor{Cluster_Blue!20} 
  Downstream signalling of activated FGFR4 & 134 &  20 & $1.1 \times 10^{-18}$ \\
  \rowcolor{Cluster_Blue!15} 
  Signalling by FGFR & 146 &  21 & $1.3 \times 10^{-18}$ \\
  \rowcolor{Cluster_Blue!20} 
  Signalling by FGFR1 & 146 &  21 & $1.3 \times 10^{-18}$ \\
  \rowcolor{Cluster_Blue!15} 
  Signalling by FGFR2 & 146 &  21 & $1.3 \times 10^{-18}$ \\
  \hline
  \\
  \rowstyle{\bfseries}
  Intersection of \gls{SLIPT} and siRNA screen (604 genes) & Pathway Size & Genes Identified & p-value (FDR) \\ 
  \hline
  \rowcolor{Cluster_Red!20!Cluster_Blue!20}
  Visual phototransduction &  54 &   9 & $6.9 \times 10^{-10}$ \\
  \rowcolor{Cluster_Red!15!Cluster_Blue!15} 
  G$_{\alpha s}$ signalling events &  48 &   7 & $1.6 \times 10^{-7}$ \\
  \rowcolor{Cluster_Red!20!Cluster_Blue!20} 
  Retinoid metabolism and transport &  24 &   5 & $1.7 \times 10^{-7}$ \\
  \rowcolor{Cluster_Red!15!Cluster_Blue!15} 
  Acyl chain remodelling of PS &  10 &   3 & $6.5 \times 10^{-6}$ \\
  \rowcolor{Cluster_Red!20!Cluster_Blue!20} 
  Transcriptional regulation of white adipocyte differentiation &  51 &   6 & $6.5 \times 10^{-6}$ \\
  \rowcolor{Cluster_Red!15!Cluster_Blue!15} 
  Chemokine receptors bind chemokines &  22 &   4 & $6.5 \times 10^{-6}$ \\
  \rowcolor{Cluster_Red!20!Cluster_Blue!20} 
  Signalling by NOTCH4 &  11 &   3 & $6.9 \times 10^{-6}$ \\
  \rowcolor{Cluster_Red!15!Cluster_Blue!15} 
  Defective EXT2 causes exostoses 2 &  11 &   3 & $6.9 \times 10^{-6}$ \\
  \rowcolor{Cluster_Red!20!Cluster_Blue!20} 
  Defective EXT1 causes exostoses 1, TRPS2 and CHDS &  11 &   3 & $6.9 \times 10^{-6}$ \\
  \rowcolor{Cluster_Red!15!Cluster_Blue!15} 
  Platelet activation, signalling and aggregation & 146 &  12 & $6.9 \times 10^{-6}$ \\
  \rowcolor{Cluster_Red!20!Cluster_Blue!20} 
  Phase 1 - Functionalisation of compounds &  41 &   5 & $1.3 \times 10^{-5}$ \\
  \rowcolor{Cluster_Red!15!Cluster_Blue!15} 
  Amine ligand-binding receptors &  13 &   3 & $1.7 \times 10^{-5}$ \\
  \rowcolor{Cluster_Red!20!Cluster_Blue!20} 
  Acyl chain remodelling of PE &  14 &   3 & $2.4 \times 10^{-5}$ \\
  \rowcolor{Cluster_Red!15!Cluster_Blue!15} 
  Signalling by GPCR & 300 &  23 & $2.4 \times 10^{-5}$ \\
  \rowcolor{Cluster_Red!20!Cluster_Blue!20} 
  Molecules associated with elastic fibres &  29 &   4 & $2.6 \times 10^{-5}$ \\
  \rowcolor{Cluster_Red!15!Cluster_Blue!15} 
  DAP12 interactions & 128 &  10 & $2.6 \times 10^{-5}$ \\
  \rowcolor{Cluster_Red!20!Cluster_Blue!20} 
  Cytochrome P$_{450}$ - arranged by substrate type &  30 &   4 & $3.2 \times 10^{-5}$ \\
  \rowcolor{Cluster_Red!15!Cluster_Blue!15} 
  GPCR ligand binding & 147 &  11 & $3.8 \times 10^{-5}$ \\
  \rowcolor{Cluster_Red!20!Cluster_Blue!20} 
  Acyl chain remodelling of PC &  16 &   3 & $4.0 \times 10^{-5}$ \\
  \rowcolor{Cluster_Red!15!Cluster_Blue!15} 
  Response to elevated platelet cytosolic Ca$^{2+}$ &  66 &   6 & $4.2 \times 10^{-5}$ \\ 
  \hline
\end{tabular}
}
\end{table*}

These pathway over-representation analyses (performed as described in Section~\ref{methods:enrichment}) correspond to genes separated into \gls{SLIPT} or siRNA screen candidates unique to either method or detected by both (Table~\ref{tab:Venn_over-representation}). The \gls{SLIPT}-specific gene candidates were involved most strongly with translational and immune regulatory pathways, although extracellular matrix pathways were also supported. These pathways were largely consistent with those identified in Table~\ref{tab:pathway_exprSL} and in the clustering analysis (Table~\ref{tab:pathway_clusters}). The genes detected only by the siRNA screen had over-represent\-ation of cell signalling pathways, including many containing genes known to be involved in cancer (e.g., MAPK, PDGF, ERBB2, and FGFR), with the detection of Class A GPCRs supporting the independent analyses by \citet{Telford2015}. The intersection of computational and experimental synthetic lethal partners of \textit{CDH1} had stronger evidence for over-represent\-ation of GPCR pathways and more specific subclasses, such as visual phototransduction ($p=6.9 \times 10^{-10}$) and G$_{\alpha s}$ signalling events ($p=1.7 \times 10^{-7}$), than other signalling pathways.

The pathway analysis for mtSLIPT against \textit{CDH1} mutations (in Table~\ref{tab:Venn_over-representation_mtSL}) had concordant results for both mtSLIPT-specific and siRNA-specific pathways. While the specific pathway composition of the intersection of these analyses differed from \gls{SLIPT} against low \textit{CDH1} expression, signalling pathways including GPCRs, NOTCH, EERB2, PDGF, and SCF-KIT. These findings indicate the signalling pathways are among the most suitable vulnerability to exploit in targeting \textit{CDH1} deficient tumours as they can be detected in both a patient cohort (with TCGA expression data) and tested in a laboratory system. However, it is possible that the isolated experimental system is set up to preferentially detect kinase singalling pathways (which are amenable to pharmacological inhibition and translation to the clinic) and the other pathways identified by \gls{SLIPT} may still be informative of the role of \textit{CDH1} loss of function in cancers or mechanisms by which further gene loss leads to specific inviability.


%%appendix
%\label{tab:Venn_over-representation_mtSL}

\FloatBarrier

\subsubsection{Resampling Genes for Pathway Enrichment} \label{chapt3:compare_pathway_perm}

Comparisons of genes between experimental screen candidates and prediction from TCGA expression data were less consistent than comparisons of pathways. However, this is not unexpected, since synthetic lethal pathways are more robustly conserved \citep{Dixon2008} and the computational approach using patient samples from complex tumour microenvironment has considerably different strengths to an experimental screen \citep{Telford2015} based on genetically homogenous cell line models in an isolated laboratory environment. For instance, it is unlikely for immune signalling to be detected in an isolated cell culture system.

\begin{figure}[!ht]
%\begin{mdframed}
  \centering
  \resizebox{0.5 \columnwidth}{!}{
    \includegraphics{sample_size_dist_exprSL_1M_Pub.png}
   }
   \caption[Resampled intersection of SLIPT and siRNA candidates]{\small \textbf{Resampled intersection of \gls{SLIPT} and siRNA candidates.} Resampling analysis of intersect size from genes detected by \gls{SLIPT} and siRNA screening approaches over 1 million replicates. The proportion of expected intersection sizes for random samples below or above the observed intersection size respectively, lacking significant over-represent\-ation or depletion of siRNA screen candidates within the \gls{SLIPT} predictions for \textit{CDH1}.
   %However, the pathway composition of this intersect may still be informative. %%covered in text
}
\label{fig:perm_sample}
%\end{mdframed}
\end{figure}

The overlap between synthetic lethal candidates from bioinformatics \gls{SLIPT} predictions and siRNA screening has raised other questions, including whether the pathways over-represented would be expected by chance. This of particular concern since the siRNA candidate genes themselves are highly over-represented for particular pathways (e.g., GPCRs) so selecting any intersect with them could be enriched for these pathways. Another pathway-based approach is to test whether pathways are over-represented in randomly sampled genes, comparing many ``resamplings'' or ``permutations'' of these genes to the enrichment statistics observed for these pathways in the \gls{SLIPT} candidates and their intersection with the siRNA hits shows whether we detect these pathways more than we expect by chance (as described in Section~\ref{methods:permutation}). 

Of particular concern are the over-represented pathways in genes detected by both methods. Pathway over-representation alone does not detect whether \gls{SLIPT} predicted genes or siRNA candidates are enriched within each other. This resampling analysis therefore detects whether over-represented pathways were detected by \gls{SLIPT} independently of their over-representation among siRNA candidates (without assuming an underlying test statistic distribution).

A resampling approach is also applicable to testing whether the number of genes detected by each approach significantly intersected. As shown in Figure~\ref{fig:perm_sample}, resampling did not find evidence of significant depletion or over-represent\-ation for experimental synthetic lethal candidate genes in the computationally predicted synthetic lethal partners of \textit{CDH1}, and thus the observed overlap may be due to chance. This is consistent with previous findings (see Figure~\ref{fig:Venn_allgenes}) and does not preclude pathway relationships being supported by resampling.

A permutation analysis was performed to resample the genes tested by both approaches to investigate whether the observed pathway over-represent\-ation could have occurred in a randomly selected sample of genes from the experimental candidates, that is, whether the pathway predictions from \gls{SLIPT} could be expected by chance (as described in Sections~\ref{methods:venn_analysis} and~\ref{methods:permutation}).
%The observed 604 genes detected by both approaches (in Figure~\ref{fig:Venn_allgenes}) was not a significantly over-represent\-ation ($p = 0.12982$) or depletion ($p = 0.85841$) of computationally predicted synthetic lethal partners of \textit{CDH1} among experimental synthetic lethal candidates (in Figure~\ref{fig:perm_sample}). This reinforces the results of the $\chi^2$ analysis,
While the number of \gls{siRNA} candidate genes also detected by \gls{SLIPT} was not statistically significant ($p=0.281$), this may be due to the vastly different limitations of the approaches and the correlation structure of gene expression not being independent (as assumed for multiple testing procedures). The  intersection may still be functionally relevant to \textit{CDH1}-deficient cancers, such as the pathway data in Table~\ref{tab:Venn_over-representation}. The resampling analysis for pathways was compared to the pathway over-represent\-ation for \gls{SLIPT} predicted synthetic lethal partners in Table~\ref{tab:pathway_perm}. Similarly, the pathway resampling for intersection between \gls{SLIPT} predictions and experimental screen candidates was compared to pathway over-represent\-ation in Table~\ref{tab:pathway_perm_overlap} for intersection with siRNA data.

The pathway resampling approach for \gls{SLIPT}-specific gene candidates (Table~\ref{tab:pathway_perm}) replicates the gene set over-represent\-ation analysis for all \gls{SLIPT} genes, detecting evidence of synthetic lethal pathways for \textit{CDH1} in translational, immune, and cell signalling pathways including  G$_{\alpha i}$ signalling, GPCR downstream signalling, and chemokine receptor binding. While the immune and signal transduction pathways were not significantly over-represented in the resampling analysis, the results for the two approaches were largely consistent for translation and post-transcriptional gene regulation, supporting gene set over-represent\-ation of the \gls{SLIPT}-specific pathways in Table~\ref{tab:pathway_perm}. In particular, some of the most significantly over-represented pathways had higher observed $\chi^2$ values than any of the 1 million random permutations. Similar pathways were also replicated by permutation analysis for mt\gls{SLIPT} candidate partners against \textit{CDH1} mutation (shown in Table~\ref{tab:pathway_perm_mtSL}). This shows that many of the pathways detected specifically by \gls{SLIPT} are replicated by permutation procedures and that the permutation approach is capable of detecting many of the most strongly over-represented pathways. 


\begin{table*}[!ht]
\caption{Pathways for \textit{CDH1} partners from SLIPT}
\label{tab:pathway_perm}
\centering
\resizebox{0.8 \textwidth}{!}{
\begin{threeparttable}
\begin{tabular}{sl^c^c}
\rowstyle{\bfseries}
 Reactome Pathway & Over-representation & Permutation \\ 
  \hline
  \rowcolor{Cluster_Red!20} 
  \textbf{Eukaryotic Translation Elongation} & $1.3 \times 10^{-207}$ & $< 1.241 \times 10^{-5}$  \\
  \rowcolor{Cluster_Red!15}  
   \textbf{Peptide chain elongation} & $5.6 \times 10^{-201}$ & $< 1.241 \times 10^{-5}$  \\
  \rowcolor{Cluster_Red!20}  
   \textbf{Viral mRNA Translation} & $1.2 \times 10^{-196}$ & $< 1.241 \times 10^{-5}$  \\
  \rowcolor{Cluster_Red!15}  
   \textbf{Eukaryotic Translation Termination} & $1.2 \times 10^{-196}$ & $< 1.241 \times 10^{-5}$  \\
  \rowcolor{Cluster_Red!20}  
   \textbf{Formation of a pool of free 40S subunits} & $3.7 \times 10^{-194}$ & $< 1.241 \times 10^{-5}$  \\
  \rowcolor{Cluster_Red!15}  
   \textbf{Nonsense Mediated Decay independent of the Exon Junction Complex} & $5.3 \times 10^{-187}$ & $< 1.241 \times 10^{-5}$  \\
  \rowcolor{Cluster_Red!20}  
   \textbf{L13a-mediated translational silencing of Ceruloplasmin expression} & $9.6 \times 10^{-183}$ & $< 1.241 \times 10^{-5}$  \\
  \rowcolor{Cluster_Red!15}  
   \textbf{3' -UTR-mediated translational regulation} & $9.6 \times 10^{-183}$ & $< 1.241 \times 10^{-5}$  \\
  \rowcolor{Cluster_Red!20}  
   \textbf{GTP hydrolysis and joining of the 60S ribosomal subunit} & $1.9 \times 10^{-181}$ & $< 1.241 \times 10^{-5}$  \\
  \rowcolor{Cluster_Red!15}  
   \textbf{Nonsense-Mediated Decay} & $6.2 \times 10^{-176}$ & $< 1.241 \times 10^{-5}$  \\
  \rowcolor{Cluster_Red!20}  
   \textbf{Nonsense Mediated Decay enhanced by the Exon Junction Complex} & $6.2 \times 10^{-176}$ & $< 1.241 \times 10^{-5}$  \\
  \rowcolor{Cluster_Red!15}  
  Adaptive Immune System & $6.5 \times 10^{-174}$ & $0.15753$ \\
  \rowcolor{Cluster_Red!20}  
  \textbf{Eukaryotic Translation Initiation} & $5.7 \times 10^{-173}$ & $< 1.241 \times 10^{-5}$  \\
  \rowcolor{Cluster_Red!15}  
  \textbf{Cap-dependent Translation Initiation} & $5.7 \times 10^{-173}$ & $< 1.241 \times 10^{-5}$  \\
  \rowcolor{Cluster_Red!20}  
  \textbf{SRP-dependent cotranslational protein targeting to membrane} & $2.0 \times 10^{-171}$ & $< 1.241 \times 10^{-5}$  \\
  \rowcolor{Cluster_Red!15}  
  \textbf{Translation} & $6.1 \times 10^{-170}$ & $< 1.241 \times 10^{-5}$  \\
  \rowcolor{Cluster_Red!20}  
  Infectious disease & $1.6 \times 10^{-166}$ & $0.23231$ \\
  \rowcolor{Cluster_Red!15}  
  \textbf{Influenza Infection} & $1.9 \times 10^{-163}$ & $< 1.241 \times 10^{-5}$  \\
  \rowcolor{Cluster_Red!20}  
  \textbf{Influenza Viral RNA Transcription and Replication} & $1.9 \times 10^{-160}$ & $< 1.241 \times 10^{-5}$  \\
  \rowcolor{Cluster_Red!15}  
  \textbf{Influenza Life Cycle} & $2.5 \times 10^{-156}$ & $< 1.241 \times 10^{-5}$  \\
  \rowcolor{Cluster_Red!20}  
  \textit{Extracellular matrix organisation} & $1.1 \times 10^{-152}$ & $0.071761$ \\
  \rowcolor{Cluster_Red!15}  
  GPCR ligand binding & $1.1 \times 10^{-143}$ & $0.55801$ \\
  \rowcolor{Cluster_Red!20}  
  Class A/1 (Rhodopsin-like receptors) & $1.5 \times 10^{-142}$ & $0.58901$ \\
  \rowcolor{Cluster_Red!15}  
  \textit{GPCR downstream signalling} & $7.6 \times 10^{-140}$ & $0.098357$ \\
  \rowcolor{Cluster_Red!20}  
  Haemostasis & $1.9 \times 10^{-134}$ & $0.27059$ \\
  \rowcolor{Cluster_Red!15}  
  Developmental Biology & $2.0 \times 10^{-123}$ & $0.52737$ \\
  \rowcolor{Cluster_Red!20}  
  Metabolism of lipids and lipoproteins & $3.3 \times 10^{-120}$ & $0.724$ \\
  \rowcolor{Cluster_Red!15}  
  Cytokine Signalling in Immune system & $2.6 \times 10^{-119}$ & $0.39661$ \\
  \rowcolor{Cluster_Red!20}  
  Peptide ligand-binding receptors & $3.7 \times 10^{-109}$ & $0.61102$ \\
  \rowcolor{Cluster_Red!15}  
  \textbf{G$_{\alpha i}$ signalling events} & $8.9 \times 10^{-100}$ & $< 1.241 \times 10^{-5}$  \\
  \iffalse
  \rowcolor{Cluster_Red!20}  
  Axon guidance & $1.4 \times 10^{-96}$ & $0.66232$ \\
  \rowcolor{Cluster_Red!15}  
  Platelet activation, signalling and aggregation & $3.7 \times 10^{-94}$ & $0.29662$ \\
  \rowcolor{Cluster_Red!20}  
  Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell & $1.4 \times 10^{-93}$ & $< 1.241 \times 10^{-5}$  \\
  \rowcolor{Cluster_Red!15}  
  Formation of the ternary complex, and subsequently, the 43S complex & $7.0 \times 10^{-91}$ & $< 1.241 \times 10^{-5}$  \\
  \rowcolor{Cluster_Red!20}  
  Translation initiation complex formation & $9.6 \times 10^{-87}$ & $6.8667 \times 10^{-5}$  \\
  \rowcolor{Cluster_Red!15}  
  Ribosomal scanning and start codon recognition & $9.6 \times 10^{-87}$ & $6.8667 \times 10^{-5}$  \\
  \rowcolor{Cluster_Red!20}  
  \begin{tabular}[c]{@{}l@{}}Activation of the mRNA upon binding of the cap-binding complex and eIFs,\\and subsequent binding to 43S \end{tabular} & $8.7 \times 10^{-86}$ & $6.8667 \times 10^{-5}$  \\
  \rowcolor{Cluster_Red!15}  
  Chemokine receptors bind chemokines & $5.1 \times 10^{-82}$ & $< 1.241 \times 10^{-5}$  \\
  \rowcolor{Cluster_Red!20}  
  Signalling by NGF & $1.2 \times 10^{-81}$ & $0.37142$ \\
  \rowcolor{Cluster_Red!15}  
  Toll-Like Receptors Cascades & $5.3 \times 10^{-80}$ & $0.63013$ \\
  \rowcolor{Cluster_Red!20}  
  Interferon gamma signalling & $6.3 \times 10^{-80}$ & $0.61493$ \\
  \rowcolor{Cluster_Red!15}  
  Transmembrane transport of small molecules & $5.3 \times 10^{-78}$ & $0.21216$ \\
  \rowcolor{Cluster_Red!20}  
  Signalling by Rho GTPases & $1.1 \times 10^{-77}$ & $0.078314$ \\
  \rowcolor{Cluster_Red!15}  
  Degradation of the extracellular matrix & $7.3 \times 10^{-77}$ & $0.769$ \\
  \rowcolor{Cluster_Red!20}  
  Interferon Signalling & $1.1 \times 10^{-76}$ & $0.18211$ \\
  \rowcolor{Cluster_Red!15}  
  NGF signalling via TRKA from the plasma membrane & $1.4 \times 10^{-74}$ & $0.60076$ \\
  \rowcolor{Cluster_Red!20}  
  Gastrin-CREB signalling pathway via PKC and MAPK & $3.1 \times 10^{-74}$ & $0.93109$ \\
  \rowcolor{Cluster_Red!15}  
  Rho GTPase cycle & $3.2 \times 10^{-73}$ & $0.11446$ \\
  \rowcolor{Cluster_Red!20}  
  DAP12 interactions & $2.0 \times 10^{-71}$ & $0.57671$ \\
  \rowcolor{Cluster_Red!15}  
  Cell surface interactions at the vascular wall & $3.3 \times 10^{-71}$ & $0.66232$ \\ 
  \fi
  \hline
\end{tabular}
\begin{tablenotes}
\raggedright \small
Over-representation (hypergeometric test) and Permutation p-values adjusted for multiple tests across pathways (FDR). Significant pathways are marked in bold (FDR $ < 0.05$) and italics (FDR $ < 0.1$).
\end{tablenotes}
\end{threeparttable}
}
\end{table*}

The permutation approach was then also applied to the intersection between computational and experimental candidates. The permutation analysis is testing for consistent detection of pathways was independent of their pre-existing status as experimental candidates. The pathway results for these candidate partners (in Table~\ref{tab:pathway_perm_overlap}) differed between over-represent\-ation and resampling analyses.

Namely, many of the over-represented pathways were not significant in the resampling analysis, including visual phototransduction and retinoic acid signalling, and were likely over-represented in the intersection due to over-represent\-ation in the \gls{siRNA} candidates rather than additional support from \gls{SLIPT}. In contrast, pathways involving defective \textit{EXT1} or \textit{EXT2} genes approach significance after FDR adjustment for multiple tests in resampling. Of the highest over-represented pathways in the intersection, only G$_{\alpha s}$ signalling events were supported by both over-represent\-ation and resampling analyses. Other pathways supported by both analyses were cytoplasmic elastic fibre formation, associated HS-GAG protein modification pathways, energy metabolism, and the fibrin clotting cascade.  

\begin{table*}[!htp]
\caption{Pathways for \textit{CDH1} partners from SLIPT and siRNA primary screen}
\label{tab:pathway_perm_overlap}
\centering
\resizebox{0.8 \textwidth}{!}{
\begin{threeparttable}
\begin{tabular}{sl^c^c}
\rowstyle{\bfseries}
 Reactome Pathway & Over-representation & Permutation \\ 
  \hline
  \rowcolor{Cluster_Red!20!Cluster_Blue!20} 
  Visual phototransduction & $6.9 \times 10^{-10}$ & $0.91116$  \\
  \rowcolor{Cluster_Red!15!Cluster_Blue!15}  
  \textbf{G$_{\alpha s}$ signalling events} & $1.6 \times 10^{-7}$ & $0.012988$  \\
  \rowcolor{Cluster_Red!20!Cluster_Blue!20}  
  Retinoid metabolism and transport & $1.7 \times 10^{-7}$ & $0.20487$  \\
  \rowcolor{Cluster_Red!15!Cluster_Blue!15}  
  Transcriptional regulation of white adipocyte differentiation & $6.5 \times 10^{-6}$ & $0.38197$  \\
  \rowcolor{Cluster_Red!20!Cluster_Blue!20}  
  Acyl chain remodelling of PS & $6.5 \times 10^{-6}$ & $0.58485$  \\
  \rowcolor{Cluster_Red!15!Cluster_Blue!15}  
  Chemokine receptors bind chemokines & $6.5 \times 10^{-6}$ & $0.97255$  \\
  \rowcolor{Cluster_Red!20!Cluster_Blue!20}  
  \textit{Defective EXT2 causes exostoses 2} & $6.9 \times 10^{-6}$ & $0.056437$  \\
  \rowcolor{Cluster_Red!15!Cluster_Blue!15}  
  \textit{Defective EXT1 causes exostoses 1, TRPS2 and CHDS} & $6.9 \times 10^{-6}$ & $0.056437$  \\
  \rowcolor{Cluster_Red!20!Cluster_Blue!20}  
  Signalling by NOTCH4 & $6.9 \times 10^{-6}$ & $0.15497$  \\
  \rowcolor{Cluster_Red!15!Cluster_Blue!15}  
  Platelet activation, signalling and aggregation & $6.9 \times 10^{-6}$ & $0.53358$  \\
  \rowcolor{Cluster_Red!20!Cluster_Blue!20}  
  Phase 1 - Functionalisation of compounds & $1.3 \times 10^{-5}$ & $0.24836$  \\
  \rowcolor{Cluster_Red!15!Cluster_Blue!15}  
  Amine ligand-binding receptors & $1.7 \times 10^{-5}$ & $0.3195$  \\
  \rowcolor{Cluster_Red!20!Cluster_Blue!20}  
  Acyl chain remodelling of PE & $2.4 \times 10^{-5}$ & $0.7307$  \\
  \rowcolor{Cluster_Red!15!Cluster_Blue!15}  
  Signalling by GPCR & $2.4 \times 10^{-5}$ & $0.9939$  \\
  \rowcolor{Cluster_Red!20!Cluster_Blue!20}  
  \textbf{Molecules associated with elastic fibres} & $2.6 \times 10^{-5}$ & $0.0072929$  \\
  \rowcolor{Cluster_Red!15!Cluster_Blue!15}  
  DAP12 interactions & $2.6 \times 10^{-5}$ & $0.78273$  \\
  \rowcolor{Cluster_Red!20!Cluster_Blue!20}  
  Cytochrome P$_{450}$ - arranged by substrate type & $3.2 \times 10^{-5}$ & $0.87019$  \\
  \rowcolor{Cluster_Red!15!Cluster_Blue!15}  
  GPCR ligand binding & $3.8 \times 10^{-5}$ & $0.99417$  \\
  \rowcolor{Cluster_Red!20!Cluster_Blue!20}  
  Acyl chain remodelling of PC & $4.0 \times 10^{-5}$ & $0.65415$  \\
  \rowcolor{Cluster_Red!15!Cluster_Blue!15}  
  Response to elevated platelet cytosolic Ca$^{2+}$ & $4.2 \times 10^{-5}$ & $0.55461$  \\
  \rowcolor{Cluster_Red!20!Cluster_Blue!20}  
  \textit{Arachidonic acid metabolism} & $4.4 \times 10^{-5}$ & $0.060298$  \\
  \rowcolor{Cluster_Red!15!Cluster_Blue!15}  
  Defective B4GALT7 causes EDS, progeroid type & $4.9 \times 10^{-5}$ & $0.15497$  \\
  \rowcolor{Cluster_Red!20!Cluster_Blue!20}  
  Defective B3GAT3 causes JDSSDHD & $4.9 \times 10^{-5}$ & $0.15497$  \\
  \rowcolor{Cluster_Red!15!Cluster_Blue!15}  
  \textbf{Elastic fibre formation} & $4.9 \times 10^{-5}$ & $0.0019227$  \\
  \rowcolor{Cluster_Red!20!Cluster_Blue!20}  
  \textbf{HS-GAG degradation} & $6.2 \times 10^{-5}$ & $0.017747$  \\
  \rowcolor{Cluster_Red!15!Cluster_Blue!15}  
  Bile acid and bile salt metabolism & $6.2 \times 10^{-5}$ & $0.15497$  \\
  \rowcolor{Cluster_Red!20!Cluster_Blue!20}  
  Netrin-1 signalling & $7.1 \times 10^{-5}$ & $0.95056$  \\
  \rowcolor{Cluster_Red!15!Cluster_Blue!15}  
  \textbf{Integration of energy metabolism} & $7.1 \times 10^{-5}$ & $0.0019287$  \\
  \rowcolor{Cluster_Red!20!Cluster_Blue!20}  
  DAP12 signalling & $7.9 \times 10^{-5}$ & $0.67835$  \\
  \rowcolor{Cluster_Red!15!Cluster_Blue!15}  
  GPCR downstream signalling & $8.1 \times 10^{-5}$ & $0.88678$  \\
  \rowcolor{Cluster_Red!20!Cluster_Blue!20}  
  \textbf{Diseases associated with glycosaminoglycan metabolism} & $8.7 \times 10^{-5}$ & $0.017747$  \\
  \rowcolor{Cluster_Red!15!Cluster_Blue!15}  
  \textbf{Diseases of glycosylation} & $8.7 \times 10^{-5}$ & $0.017747$  \\
  \rowcolor{Cluster_Red!20!Cluster_Blue!20}  
  Signalling by Retinoic Acid & $8.7 \times 10^{-5}$ & $0.13592$  \\
  \rowcolor{Cluster_Red!15!Cluster_Blue!15}  
  Signalling by Leptin & $8.7 \times 10^{-5}$ & $0.15497$  \\
  \rowcolor{Cluster_Red!20!Cluster_Blue!20}  
  Signalling by SCF-KIT & $8.7 \times 10^{-5}$ & $0.73399$  \\
  \rowcolor{Cluster_Red!15!Cluster_Blue!15}  
  Opioid Signalling & $8.7 \times 10^{-5}$ & $0.99417$  \\
  \rowcolor{Cluster_Red!20!Cluster_Blue!20}  
  Signalling by NOTCH & $0.0001$ & $0.26453$  \\
  \rowcolor{Cluster_Red!15!Cluster_Blue!15}  
  Platelet homeostasis & $0.0001$ & $0.55912$  \\
  \rowcolor{Cluster_Red!20!Cluster_Blue!20}  
  Signalling by NOTCH1 & $0.00011$ & $0.13797$  \\
  \rowcolor{Cluster_Red!15!Cluster_Blue!15}  
  Class B/2 (Secretin family receptors) & $0.00011$ & $0.4659$  \\
  \rowcolor{Cluster_Red!20!Cluster_Blue!20}  
  Diseases of Immune System & $0.00013$ & $0.15497$  \\
  \rowcolor{Cluster_Red!15!Cluster_Blue!15}  
  Diseases associated with the TLR signalling cascade & $0.00013$ & $0.15497$  \\
  \rowcolor{Cluster_Red!20!Cluster_Blue!20}  
  A tetrasaccharide linker sequence is required for GAG synthesis & $0.00013$ & $0.33566$  \\
  \rowcolor{Cluster_Red!15!Cluster_Blue!15}  
  Nuclear Receptor transcription pathway & $0.00016$ & $0.22735$  \\
  \rowcolor{Cluster_Red!20!Cluster_Blue!20}  
  \textbf{Formation of Fibrin Clot (Clotting Cascade)} & $0.00016$ & $0.0054639$  \\
  \rowcolor{Cluster_Red!15!Cluster_Blue!15}  
  Syndecan interactions & $0.00016$ & $0.3974$  \\
  \rowcolor{Cluster_Red!20!Cluster_Blue!20}  
  Class A/1 (Rhodopsin-like receptors) & $0.00016$ & $0.99454$  \\
  \rowcolor{Cluster_Red!15!Cluster_Blue!15}  
  HS-GAG biosynthesis & $0.0002$ & $0.37199$  \\
  \rowcolor{Cluster_Red!20!Cluster_Blue!20}  
  Platelet degranulation  & $0.0002$ & $0.39003$  \\
  \rowcolor{Cluster_Red!15!Cluster_Blue!15}  
  EPH-ephrin mediated repulsion of cells & $0.00021$ & $0.6193$  \\ 
  \hline
\end{tabular}
\begin{tablenotes}
\raggedright \small
Over-representation (hypergeometric test) and Permutation p-values adjusted for multiple tests across pathways (FDR). Significant pathways are marked in bold (FDR $ < 0.05$) and italics (FDR $ < 0.1$).
\end{tablenotes}
\end{threeparttable}
}
\end{table*}

Many of the pathways supported in the intersection by permutation analysis were also replicated in the mtSLIPT analysis of partners tested with \textit{CDH1} mutation (in Table~\ref{tab:pathway_perm_overlap_mtSL}), including G$_{\alpha s}$, elastic fibres, HS-GAG, and energy metabolism. While there were differences between the pathways identified by over-representation analysis, those replicated by permutation were highly concordant, supportig the combined use of these pathway approaches to identify synthetic lethal gene functions and targets. 

While this indicates that G$_{\alpha s}$ and GPCR class A/1 signalling events were significantly detected by both approaches, GPCR signalling pathways overall were not. It is likely that GPCRs were primarily over-represented in the intersection with the experimental candidates due to strong over-represent\-ation of these pathways in experimental candidates, rather than detection by \gls{SLIPT}, which may be driven by these more specific constituent pathways. 

%% remove paragraph?
However, several pathways, including some immune functions and neurotransmitters, were supported by the resampling analysis (in Tables~\ref{tab:pathway_perm_overlap} and~\ref{tab:pathway_perm_overlap_mtSL}) when the initial pathway over-represent\-ation test was not significant. These functions appear to have been detected by both approaches  more than expected by chance but must be interpreted with caution since they were still not common enough to be detected in pathway over-represent\-ation analysis.

\subsection{Integrating Synthetic Lethal Pathways and Screens}

Based on these results, it appears that computational and experimental approaches to synthetic lethal screening for \textit{CDH1} lead to a broader functional characterisation, and many candidate partners, when combined, despite different strengths and limitations. Compared to candidate gene approaches, experimental genome-wide screens are an appealing unbiased strategy for identifying synthetic lethal interactions. Since these screens are costly, laborious, and specific to genetic background, computational analysis can augment candidate triage to either reduce the initial panel of screened genes or prioritise validation.

GPCR pathways were detected among both computational and experimental synthetic lethal candidates, with more support in the experimental screen (Table~\ref{tab:pathway_perm_overlap}). The homogeneous cell line model may be more likely to detect particular pathways. For instance, \gls{SLIPT} identified immune pathways, not expected to be detected in isolated cell culture. GPCR signalling was supported in experimental models \cite{Telford2015} with some of these pathways replicated in varied genetic backgrounds of patient samples. These pathways require further investigation such as identification of more specific pathways, higher order interactions, and modes of resistance.

The pathway composition across computational and experimental synthetic lethal candidates was informative with over-represent\-ation (Table~\ref{tab:Venn_over-representation}) and supported by resampling analysis (Table~\ref{tab:pathway_perm_overlap}), despite a modest intersection of genes between them (Figure~\ref{fig:Venn_allgenes}).
Either approach may be significant for a pathway in this intersection without being supported by the other: resampling analysis may support pathways that were not over-represent\-ed due to small effect sizes, thus both tests are required for a candidate pathway.
The pathways detected by both over-represent\-ation and resampling are the strongest candidates for further investigation, such as G$_{\alpha s}$ signalling, a strong candidate in prior analyses with a role in the regulation of translation in cancer \cite{Gao2015}, another function supported by \gls{SLIPT} analysis.
%The bioinformatics analysis demonstrated here could be integrated into future screening for synthetic lethality in cancer.  

The predicted synthetic lethal partners occurred across functionally distinct pathways, including characterised functions of \textit{CDH1}. This diversity is consistent with the wide ranging role of \textit{CDH1} in cell-cell adhesion, cell signalling, and the cytoskeletal structure of epithelial tissues. Pathway structure may be relevant to identifying potential drug targets from gene expression signatures, indicating downstream effector genes and mechanisms leading to cell inviability. These distinct synthetic lethal gene clusters and pathways may further lead to the elucidation of drug resistance mechanisms.

%%appendix
%\label{tab:pathway_perm_mtSL}
%\label{tab:pathway_perm_overlap_mtSL}

\FloatBarrier

%\subsubsection{Comparison of Candidate SL Pathways}
%committee
%Thus we have identified candidate synthetic lethal pathways by gene set over-representation, metagene synthetic lethality, and re-sampled empirical pathway over-representation. The challenge currently under consideration is whether these methods can be compared and which may lead to biologically meaningful or clinically relevant synthetic lethal candidate pathways.
%\FloatBarrier

\iffalse

\section{Mutation, Copy Number, and Methylation}

Due to promising synthetic lethal data on mutation and DNA copy number analyses \citep{Jerby2014, Lu2015}, these were also investigated to compare genes for synthetic lethality in an analogous manner to expression analyses in the TCGA data. Due to the low somatic mutation rate (and lack of available) germline mutations for many genes, it was not possible to detect many double mutations with significantly under-representation in cancers. There were also concerns about using rare mutations with unknown significance or excluding functional mutations by only using those in the exons.
It was possible to compare deletion and duplication of DNA copy number in a manner analogous to expression quantiles. However, these overlapped poorly with candidate interacting partners from expression analyses and concerns were raised that they may not be relevant to \textit{CDH1} which is typically inactivated in tumours by loss of function mutations or DNA methylation (PJ Guilford, personal communication).   

DNA methylation data was also prepared for synthetic lethal analysis but was discontinued due to computational challenges, expected similarity to expression results, difficulty defining loss of function methylation at a gene level across CpG sites, and the concerns raised in the next section. 

\subsection{Synthetic lethality by DNA copy number}


\fi


\section{Metagene Analysis}  \label{chapt3:metagene_results}
%[include?]

The gene signatures \citep{Gatza2011, Gatza2014} were used to demonstrate to utility of the metagene approach for use on a wider range of pathways as was performed with the Reactome \citep{Reactome} pathways as an alternative approach to identification of synthetic lethal pathways. Metagenes serve as a summary of activity for each pathway. The direction of metagenes (derived by the singular value matrix decomposition) is generally arbitrary but care has been taken to ensure that these occur in a direction which reflect overall activation of the pathway (as described in Section~\ref{methods:metagene}). Metagenes were derived for well characterised gene signatures in breast cancer \citep{Gatza2011, Gatza2014} to verify that that these pathway signatures are consistent with expected molecular properties of each molecular subtype \citep{Perou2000, Parker2009}. This was performed by examining the pathway expression of these breast cancer gene signatures in TCGA expression data. These metagenes were also compared to somatic mutation to evaluate mutation as a measure of gene activity in comparison to gene and protein expression.

The gene signatures \citep{Gatza2011, Gatza2014} were used to demonstrate to utility of the metagene approach for use on a wider range of pathways. Having established that metagenes generated with this procedure reflect gene activity, the metagene procedure (in Section~\ref{methods:metagene}) was then applied to the Reactome pathways \citep{Reactome}. These Reactome metagenes were used for synthetic lethal analysis of pathways with \gls{SLIPT}, directly using pathway activity for identifying synthetic lethal pathways with \textit{CDH1}.

\subsection{Pathway Expression} \label{chapt3:metagene_expression}

Pathway metagenes (generated as described in Section~\ref{methods:metagene}) for gene signatures of key processes in breast cancer \citep{Gatza2011} were used to check that metagenes were generated in the correct direction to indicate pathway activation. Some of these gene signatures are plotted in Figure~\ref{fig:metagene_expr_Gatza2011} for comparison with clinical factors and somatic mutations. The ``intrinsic subtype''  was computed by performing the \gls{PAM50} procedure \cite{Parker2009} for RNASeq data which was highly concordant ($\chi^2 = 1305.9$, $p = 2.73 \times 10^{-268}$) with the subtypes provided by \gls{UCSC} for TCGA samples  \citep{TCGA2012} previously analysed by microarrays (as shown in Appendix \ref{appendix:intrinsic_subtypes}). Somatic mutations were reported for recurrently mutated genes in breast cancer, as reported by TCGA \citep{TCGA2012}, related genes, and those previously discussed to be important in hereditary breast cancers (\textit{BRCA1}, \textit{BRCA2}, and \textit{CDH1}).

\begin{figure*}[!htp]
\noindent\makebox[\textwidth][c]{%               %centering
%\noindent\fbox{
\begin{minipage}{1.00 \textwidth}  %frame beyond textwidth
\begin{center}
  \resizebox{1 \textwidth}{!}{
    \includegraphics{CDH1_Heatmaps_Gatza2011(ranked)_Full_split_by_Subtype_and_CDH1_Stat_corr2.pdf} %original pdf, png for edited %1.png = Gatza 2011, 2.png = Cropped, 3.png = excl. PI3K
   }
   \end{center}
   \caption[Pathway metagene expression profiles]{\small \textbf{Pathway metagene expression profiles.} Expression profiles for metagene signatures from \citet{Gatza2011} in TCGA breast data, annotated for clinical factors (with sample types and histological results coloured according to the legend) and cancer gene mutations (Negative values for mutation are light grey with missing data in white). Intrinsic subtypes are shown as derived from microarray (\gls{UCSC}) and \gls{RNA-Seq} (\gls{PAM50}) data \citep{TCGA2012, Parker2009}. Samples were clustered independently for each intrinsic subtype and by \textit{CDH1} expression status. Pathway expression signatures are consistent with mutations and clinical subgroups.
}
\label{fig:metagene_expr_Gatza2011}
\end{minipage}
%} %close fbox
} %close centering
\end{figure*}

These gene signatures reflect intrinsic subtypes as expected. In particular, the estrogen and progesterone receptor signatures are low in the predominantly ER$^-$ and PR$^-$ basal-like subtype tumours. These tumours also had the highest frequency of \textit{TP53} mutations and a corresponding reduction of p53 metagene activity, as expected for loss of a tumour suppressor. The luminal A and luminal B tumour subtypes are the most similar, which is reflected in these metagenes signatures, although they are distinguishable molecular subtypes as shown by elevated \gls{PI3K}, AKT, RAS, and $\beta$-catenin signalling in luminal B tumours. However, these pathways were also elevated in basal-like and HER2-enriched subtypes and lowly expressed in the ``normal-like'' subtype (which contained the normal samples). These intrinsic subtype specific gene signature profiles were further supported with metagenes for an extended set of signatures \citep{Gatza2014}, as shown in Figure~\ref{fig:metagene_expr_Gatza2014}.

\textit{TP53} mutations were the most frequent and more common in the basal-like subtype. Similarly, \textit{GATA3} mutations were more common in luminal subtype tumours. \gls{PI3K} mutations were more frequent across breast tumours, although these were less common in the basal-like subtype despite an elevated metagene (this discrepancy will the discussed further in Section~\ref{chapt3:metagene_mut}). \textit{CDH1} mutations similarly occurred across molecular subtypes with the exception of the basal-like subtype (as observed in gene expression with Figure~\ref{fig:slipt_expr}). \textit{CDH1} low samples occurred in all subtypes but were predominantly of the lobular histological ubtype. Apart from these genes, mutations did not show clear specificity to a particular subtype and the variation between samples reflects the range of molecular cascades that can result in tumours with similar molecular profiles, supporting the use of gene expression data for cancer diagnostics and identification of molecular targets. 

The direction of each metagene was consistent with the clinical characteristics, which formed a consensus of gene activity as shown for the \gls{PI3K} and ER signatures \citep{Gatza2011} in Figures~\ref{fig:metagene_expr_Gatza2011_PI3K} and~\ref{fig:metagene_expr_Gatza2011_ER}, respectively.  Supporting data for p53 and BRCA metagenes \citep{Gatza2011, Gatza2014} are given in the Appendix (Figures~\ref{fig:metagene_expr_Gatza2011_P53} and~\ref{fig:metagene_expr_Gatza2014_BRCA}). In each of the examples for gene signatures% for PI3K (Figure~\ref{fig:metagene_expr_Gatza2011_PI3K}), p53 (Figure~\ref{fig:metagene_expr_Gatza2011_P53}), estrogen receptor (Figure~\ref{fig:metagene_expr_Gatza2011_ER}), and BRCA (Figure~\ref{fig:metagene_expr_Gatza2014_BRCA}) genes \citep{Gatza2011, Gatza2014}
, the expression of the majority of the genes were highly concordant with the metagene, being either positively or negatively correlated. These were generally consistent with established clinical and molecular subtypes of breast cancer and the recurrent mutations shown. However, the \textit{PIK3CA} and \textit{PIK3R1} mutant samples did not necessarily have elevated PI3K pathway metagene activity (as shown in Figure~\ref{fig:metagene_expr_Gatza2011_PI3K}).  


\begin{figure*}[!htp]
\noindent\makebox[\textwidth][c]{%               %centering
%\noindent\fbox{
\begin{minipage}{1.15 \textwidth}  %frame beyond textwidth
\begin{center}
  \resizebox{1 \textwidth}{!}{
    \includegraphics{CDH1_Heatmaps_Gatza2011(PI3K)_Full_Metagene_mgorder.png} %original pdf, png for edited
   }
   \end{center}
   \caption[Expression profiles for constituent genes of PI3K]{\small \textbf{Expression profiles for constituent genes of PI3K.} Expression profiles the genes contained in the PI3K gene signature from \citet{Gatza2011} in TCGA breast data, annotated for clinical factors and cancer gene mutations. Samples are separated by \textit{CDH1} expression status and sorted by the metagene. In both cases, the majority of genes were consistent with the direction of the PI3K metagene, although considerable proportion were inversely correlated with the metagene. Normal samples had low PI3K metagene expression and \textit{TP53} mutant samples had high PI3K expression. Although, oncogenic \textit{PIK3CA} and tumour suppressor \textit{PIK3R1} mutations across samples including those with low metagene response.
}
\label{fig:metagene_expr_Gatza2011_PI3K}
\end{minipage}
%} %close fbox
} %close centering
\end{figure*}

\begin{figure*}[!htp]
\noindent\makebox[\textwidth][c]{%               %centering
%\noindent\fbox{
\begin{minipage}{1.15 \textwidth}  %frame beyond textwidth
\begin{center}
  \resizebox{1 \textwidth}{!}{
    \includegraphics{CDH1_Heatmaps_Gatza2011(ER)_Full_Metagene_mgorder.png} %original pdf, png for edited
   }
   \end{center}
   \caption[Expression profiles for estrogen receptor related genes]{\small \textbf{Expression profiles for estrogen receptor related genes.} Expression profiles the genes contained in the estrogen receptor (ER) gene signature from \citet{Gatza2011} in TCGA breast data, annotated for clinical factors and cancer gene mutations. Samples are separated by \textit{CDH1} expression status and sorted by the metagene. In both cases, the majority of genes were consistent with the direction of the metagene, with very few exceptions being inversely correlated. Estrogen receptor (by antibody staining) negative samples had low  metagene expression, as expected. These were more likely to be ductal and basal subtypes, lacking \textit{CDH1} or \textit{PIK3CA} mutations.
}
\label{fig:metagene_expr_Gatza2011_ER}
\end{minipage}
%} %close fbox
} %close centering
\end{figure*}


%\FloatBarrier

\subsection{Somatic Mutation}  \label{chapt3:metagene_mut}



\begin{figure*}[!ht]
%\begin{mdframed}
        \begin{center}
%
        \subcaptionbox{\textit{PIK3CA}}{%
           \includegraphics[width=0.35\textwidth]{metagene(ranked)_vioplotx_Mutation_PI3K2011_PIK3CA.pdf}
        }%
        \subcaptionbox{\textit{PIK3CA} or \textit{PIK3R1}}{%
           \includegraphics[width=0.35\textwidth]{metagene(ranked)_vioplotx_Mutation_PI3K2011_PIK3CA_PIK3R1.pdf}
        }
        
        \subcaptionbox{\textit{CDH1}}{%
           \includegraphics[width=0.35\textwidth]{metagene(ranked)_vioplotx_Mutation_PI3K2011_CDH1.pdf}
        }%
        \subcaptionbox{\textit{TP53}}{%
           \includegraphics[width=0.35\textwidth]{metagene(ranked)_vioplotx_Mutation_PI3K2011_TP53.pdf}
        }
    \end{center}
    \caption[Somatic mutation against the PI3K metagene]{\small \textbf{Somatic mutation against the \gls{PI3K} metagene.} Mutations in \textit{PIK3CA}, \textit{PIK3R1}, \textit{CDH1}, and \textit{TP53} were examined in \gls{TCGA} breast cancer for their association with the \gls{PI3K} \citep{Gatza2011} pathway metagene. The tumour suppressors \textit{CDH1} and \textit{TP53} showed an increase and decrease in the metagene respectively, whereas \textit{PIK3CA} and \textit{PIK3R1} mutations had little effect on the metagene levels.
}
\label{fig:mutation_expr_mg}
%\end{mdframed}
\end{figure*}

It should be noted that metagenes, while consistent with the consensus of constituent expressed genes, were not necessarily reflecting the somatic mutation status. The PI3K \citep{Gatza2011} metagene levels in particular, were not statistically significantly varying between mutant and wildtype \textit{PIK3CA} samples (shown in Figure~\ref{fig:mutation_expr_mg}). However, the PI3K metagene differed across \textit{CDH1} and \textit{TP53} mutations, remarkably in opposite directions considering that PI3K is an oncogenic growth pathway and these are both most frequently tumour suppressors inactivated in cancers. This shows that \textit{CDH1} and \textit{TP53} deficient tumours have distinct molecular growth pathways and that synthetic lethal interventions against loss of \textit{CDH1} function may not be applicable to other cancers with driver mutations such as \textit{TP53}, although these were kept in the analysis for comparison. These differences may be related to these mutations being more frequent in tumours with difference clinical characteristics (as observed in Section~\ref{chapt3:metagene_expression}).  Thus mutations do not necessarily have corresponding changes in pathway expression, particularly for oncogenes which may change in function rather than being upregulated.


While the more specific \textit{PIK3CA} \citep{Gatza2014} metagene showed significant differences with \textit{PIK3CA} and \textit{PIK3R1} mutations (as shown in Figure~\ref{fig:mutation_expr_mg2}), this metagene replicated stronger differences for \textit{CDH1} and \textit{TP53}.  These differences were less pronounced in the protein levels of p110$\alpha$ (enocded by \textit{PIK3CA}) and the downstream AKT gene (shown in Figures~\ref{fig:mutation_expr_prot} and~\ref{fig:mutation_expr_prot2} respectively). However, this may be due to this regulatory cascade (kinases) being transmitted as a change in protein state (phosphorylation) rather than changes in expression levels. Another consideration is that mutations at different loci have different effects on protein function, particularly for oncogenes.

\FloatBarrier

\iffalse
\subsection{Mutation locus}  \label{chapt3:metagene_mut_locus}

The gene locus distribution of \textit{PIK3CA} and it's receptor \textit{PIK3R1} were consistent with oncogenic and tumour suppressor mutations, as shown in Figure~\ref{fig:mutation_locus}. \textit{PIK3CA} has recurrent mutations in 2 hotspots, centered around the E545K and H1047R (shown in Figure~\ref{fig:mutation_locus:PIK3CA}), as expected for an oncogene. This contrasts with the tumour suppressors, \textit{PIK3R1}, and \textit{CDH1} (shown in Figures~\ref{fig:mutation_locus:PIK3R1} and~\ref{fig:mutation_locus:CDH1} respectively), which have low frequency inactivating mutations spread across them. A notable exception is \textit{TP53} (shown in Figure~\ref{fig:mutation_locus:TP53}) which displays both inactivating mutations throughout and recurrent (oncogenic) mutations at high frequency, consistent with the complex role of \textit{TP53} in cancer biology which is outside of the scope of this thesis and shown for comparison. 


\begin{figure*}[!ht]
%\begin{mdframed}
        \begin{center}
%
        \subcaptionbox{\textit{PI3KCA} gene}{%
            %\label{fig:simulate_function:first}
            \includegraphics[width=0.3\textwidth]{geneexpr_vioplotx_Mutation_locus_PIK3CA.pdf}
        }%
        \subcaptionbox{\textit{PI3KCA} metagene}{%
            %\label{fig:simulate_function:first}
            \includegraphics[width=0.3\textwidth]{metagene_vioplotx_Mutation_locus_PIK3CA.pdf}
        }%
        \subcaptionbox{\textit{PIK3R1} gene}{%
           \includegraphics[width=0.3\textwidth]{geneexpr_vioplotx_Mutation_locus_PIK3R1.pdf}
        }
        
        \subcaptionbox{\textit{PIK3CA} protein}{%
           \includegraphics[width=0.3\textwidth]{protein_vioplotx_Mutation_locus_PIK3CA.pdf}
        }%
        \subcaptionbox{\textit{AKT} protein}{%
           \includegraphics[width=0.3\textwidth]{protein_vioplotx_Mutation_locus_AKT.pdf}
        }
        
        \subcaptionbox{\textit{CDH1} protein}{%
           \includegraphics[width=0.3\textwidth]{protein_vioplotx_Mutation_locus_CDH1.pdf}
        }%
        \subcaptionbox{\textit{TP53} protein}{%
           \includegraphics[width=0.3\textwidth]{protein_vioplotx_Mutation_locus_TP53.pdf}
        }
    \end{center}
    \caption[Somatic mutation locus against expression]{\small \textbf{Somatic mutation locus against expression.} The recurrent E545K and H1047R oncogene mutations in \textit{PIK3CA} were examined in TCGA breast cancer to show the effect of mutation locus on gene, pathway, and protein expression. While neither of these mutations had an impact of \textit{PIK3CA} mRNA expression, E545K had specifically lower PI3K \citep{Gatza2011} metagene levels and both mutations had higher \textit{PIK3R1} mRNA expression. However, these differences were not reflected in the protein expression levels.
}
\label{fig:mutation_expr}
%\end{mdframed}
\end{figure*}

These differences in gene locus may explain why mutations do not necessarily have corresponding changes in gene or metagene expression. Specfically, the recurrent E545K and H1047R oncogene mutations in \textit{PIK3CA} did not affect \textit{PIK3CA} mRNA expression but E545K had specifically lower PI3K \citep{Gatza2011} metagene levels. Both mutations had higher \textit{PIK3R1} mRNA expression but these differences differences were not reflected in the protein expression levels of p110$\alpha$ protein (encoded by \textit{PIK3CA}), it's downstream target AKT, E-cadherin (encoded by \text{CDH1}), or p53 (as ashown in Figure~\ref{fig:mutation_expr}).

While the complex effects of mutation in oncogenes such as \textit{PIK3CA} are not necessarily detected in a pathway metagene, these do capture the consensus of pathway gene expression and account for other potential means of pathway activation. Thus metagenes are sufficient as a measure of gene activity for the purposes of synthetic lethal detection with \gls{SLIPT}. This approach is more applicable to tumour suppressor genes with a relationship between gene expression and activity (rather than activation at the protein level) but this is not a major concern since synthetic lethality is more clinically relevant for targeting tumour suppressor mutations than oncogenes.
\fi


\FloatBarrier

\subsection{Synthetic Lethal Pathway Metagenes} \label{chapt3:metagene_SL}

Pathway metagenes for Reactome pathways (generated as described in Section~\ref{methods:metagene}) were also used for testing synthetic lethal partner pathways with \textit{CDH1} by \gls{SLIPT}. Since the metagenes have are higher when the pathway as a whole is activated, they are amenable to \gls{SLIPT} analysis using low metagene levels for inactivated pathways. These synthetic lethal metagenes differed to the over-represented pathways among synthetic lethal gene candidates. However, there were some similarities to previous findings, as shown in Tables~\ref{tab:metagene_SL}. In particular, translational pathways were replicated as observed in Table~\ref{tab:pathway_exprSL}. While the specific pathways differ, immune pathways (e.g., NF-$\kappa$B) were also supported by metagene synthetic lethal analysis.

\begin{table*}[!ht]
\caption{Candidate synthetic lethal metagenes against \textit{CDH1} from SLIPT}
\label{tab:metagene_SL}
\centering
\resizebox{1 \textwidth}{!}{
\begin{threeparttable}
\begin{tabular}{sl^l^c^c^c^c^c}
\rowstyle{\bfseries}
 Pathway & ID & Observed & Expected & $\chi^2$value & p-value & p-value (FDR) \\ 
  \hline
  \rowcolor{black!10}
  Glycogen storage diseases & 3229121 & 68 & 130 & 176 & $6.62 \times 10^{-37}$ & $1.82 \times 10^{-34}$ \\ 
  \rowcolor{black!5}
  Myoclonic epilepsy of Lafora & 3785653 & 68 & 130 & 176 & $6.62 \times 10^{-37}$ & $1.82 \times 10^{-34}$ \\ 
  \rowcolor{black!10}
  Diseases of carbohydrate metabolism & 5663084 & 68 & 130 & 176 & $6.62 \times 10^{-37}$ & $1.82 \times 10^{-34}$ \\ 
  \rowcolor{black!5}
  Arachidonic acid metabolism & 2142753 & 81 & 130 & 157 & $8.13 \times 10^{-33}$ & $1.49 \times 10^{-30}$ \\ 
  \rowcolor{black!10}
  Translation initiation complex formation & 72649 & 70 & 130 & 152 & $7.08 \times 10^{-32}$ & $1.17 \times 10^{-29}$ \\ 
  \rowcolor{black!5}
  Synthesis of 5-eicosatetraenoic acids & 2142688 & 68 & 130 & 151 & $1.25 \times 10^{-31}$ & $1.88 \times 10^{-29}$ \\ 
  \rowcolor{black!10}
  SRP-dependent cotranslational protein targeting to membrane & 1799339 & 69 & 130 & 150 & $2.01 \times 10^{-31}$ & $2.76 \times 10^{-29}$ \\ 
  \rowcolor{black!5}
  L13a-mediated translational silencing of Ceruloplasmin expression & 156827 & 72 & 130 & 148 & $5.91 \times 10^{-31}$ & $6.44 \times 10^{-29}$ \\ 
  \rowcolor{black!10}
  3' -UTR-mediated translational regulation & 157279 & 72 & 130 & 148 & $5.91 \times 10^{-31}$ & $6.44 \times 10^{-29}$ \\ 
  \rowcolor{black!5}
  \begin{tabular}[c]{@{}l@{}}Activation of the mRNA upon binding of the cap-binding complex and eIFs,\\and subsequent binding to 43S \end{tabular} & 72662 & 70 & 130 & 147 & $1.14 \times 10^{-30}$ & $9.28 \times 10^{-29}$ \\ 
  \rowcolor{black!10}
  Formation of the ternary complex, and subsequently, the 43S complex & 72695 & 70 & 130 & 147 & $1.14 \times 10^{-30}$ & $9.28 \times 10^{-29}$ \\ 
  \rowcolor{black!5}
  Ribosomal scanning and start codon recognition & 72702 & 70 & 130 & 147 & $1.14 \times 10^{-30}$ & $9.28 \times 10^{-29}$ \\ 
  \rowcolor{black!10}
  Eukaryotic Translation Elongation & 156842 & 72 & 130 & 146 & $1.19 \times 10^{-30}$ & $9.28 \times 10^{-29}$ \\ 
  \rowcolor{black!5}
  Nonsense Mediated Decay independent of the Exon Junction Complex & 975956 & 71 & 130 & 146 & $1.24 \times 10^{-30}$ & $9.28 \times 10^{-29}$ \\ 
  \rowcolor{black!10}
  Viral mRNA Translation & 192823 & 70 & 130 & 146 & $1.51 \times 10^{-30}$ & $1.04 \times 10^{-28}$ \\ 
  \rowcolor{black!5}
  Eukaryotic Translation Termination & 72764 & 70 & 130 & 146 & $1.51 \times 10^{-30}$ & $1.04 \times 10^{-28}$ \\ 
  \rowcolor{black!10}
  NF-kB is activated and signals survival & 209560 & 71 & 130 & 145 & $1.90 \times 10^{-30}$ & $1.19 \times 10^{-28}$ \\ 
  \rowcolor{black!5}
  Peptide chain elongation & 156902 & 72 & 130 & 145 & $1.91 \times 10^{-30}$ & $1.19 \times 10^{-28}$ \\ 
  \rowcolor{black!10}
  Influenza Life Cycle & 168255 & 70 & 130 & 145 & $1.95 \times 10^{-30}$ & $1.19 \times 10^{-28}$ \\ 
  \rowcolor{black!5}
  Formation of a pool of free 40S subunits & 72689 & 73 & 130 & 145 & $2.01 \times 10^{-30}$ & $1.19 \times 10^{-28}$ \\ 
  \rowcolor{black!10}
  Nonsense-Mediated Decay & 927802 & 71 & 130 & 145 & $2.44 \times 10^{-30}$ & $1.34 \times 10^{-28}$ \\ 
  \rowcolor{black!5}
  Nonsense Mediated Decay enhanced by the Exon Junction Complex & 975957 & 71 & 130 & 145 & $2.44 \times 10^{-30}$ & $1.34 \times 10^{-28}$ \\ 
  \rowcolor{black!10}
  GTP hydrolysis and joining of the 60S ribosomal subunit & 72706 & 72 & 130 & 145 & $2.58 \times 10^{-30}$ & $1.37 \times 10^{-28}$ \\ 
  \rowcolor{black!5}
  Influenza Viral RNA Transcription and Replication & 168273 & 72 & 130 & 144 & $4.01 \times 10^{-30}$ & $2.07 \times 10^{-28}$ \\ 
  \rowcolor{black!10}
  Signalling by NOTCH1 HD Domain Mutants in Cancer & 2691230 & 79 & 130 & 143 & $5.99 \times 10^{-30}$ & $2.82 \times 10^{-28}$ \\ 
  \hline
\end{tabular}
\begin{tablenotes}
\raggedright \small
Strongest candidate SL partners for \textit{CDH1} by \gls{SLIPT} with observed and expected numbers of \gls{TCGA} breast cancer samples with low expression of both \textit{CDH1} and the metagene.
\end{tablenotes}
\end{threeparttable}
}
\end{table*}

Signalling pathways were more strongly supported by mtSLIPT analysis of metagene pathway expression against \textit{CDH1} mutation, as shown in Table~\ref{tab:metagene_mtSL}, although these results were generally less statistically significant than expression analyses. Signalling pathways detected as synthetic lethal metagenes include G$_{\alpha z}$, insulin-related growth factor (IGF), GABA receptor, G$_{\alpha s}$, S6K1 and various toxin responses mediated by GPCRs. Metabolic processes including processing of carbohydrates and fatty acids were also implicated across these analyses.

The metagene analyses differ more between expresssion and \textit{CDH1} mutation than previous analyses, with more specific signalling pathways identified in the mutation analysis. This supports the usage of a complete null mutant model in experimental testing for synthetic lethality of signalling pathways against \text{CDH1} inactivation rather than a knockdown in expression. However, low expression of partners has been used in either case to be applicable to dose-dependent pharmacological inhibition and across genes where mutations have different functional consequences, including variants of unknown significance. 

These results show an independent pathway-based approach to detecting synthetic lethal gene functions interacting with \textit{CDH1}. The use of synthetic lethal metagenes replicates support for these pathways independent of pathway size (as genes are weighted equally). Along with the verifying that the direction of metagenes recapitulates the activity of a pathway, these demonstrate that many of the pathways previously identified from over-represent\-ed synthetic lethal genes (detected by \gls{SLIPT}) are synthetic lethal pathways with their activity dependent on synthetic lethal genes rather than containing synthetic lethal genes as inhibitors or peripheral regulators of the pathways.

\subsection{Synthetic Lethality in Breast Cancer}

The synthetic lethal analysis against low \textit{CDH1} expression supports prior findings in translational and immune pathways even if they were not able to detected in an experimental screen \citep{Telford2015}. Together these findings support the role of \textit{CDH1} loss in cancer disrupting cell signalling with wider effects on protein translation and metabolism necessary for the proliferation of cancer cells. This is consistent with the GPCR pathways such as G$_{\alpha s}$ signalling being supported by \gls{SLIPT} gene candidates and the experimental primary siRNA screen, as shown by resampling in Section~\ref{chapt3:compare_pathway_perm}.

%%appendix
%\label{tab:metagene_mtSL}

\FloatBarrier

%\section{Synthetic Lethality by Somatic Mutation}

%\section{Mutation analysis}
%Data in Appendix~\ref{appendix:mutation_analysis} %%discussed above

\iffalse
\subsection{ANOVA of Expression Predictors}
[include?]

Another approach was to only use copy number, mutation, or hyper-methylation data for genes in which they would impact on gene function and occur frequently in tumours. Before investigating whether these impact on gene function, they were investigated as predictors of variation in gene expression. If these are not giving variation independent of gene expression, expression would be a more suitable measure of gene function as it is widely generated in studies and useful as a clinical biomarker.

Globally predicting gene expression across all genes from DNA copy number and somatic mutation was attempted by ANOVA. However, this was computationally challenging and gene-specific analyses would be more informative. Gene specific ANOVA and linear regression was performed but was raised more issues than it addressed. There were issues with interaction terms and mutation data, many genes were not tested for these since there were so few mutations for these genes in the dataset.  It was possible to include DNA methylation in gene-specific analyses (despite the concerns raised above) but the $R^2$ values for each gene were still generally very low and issues with insufficient mutant samples for interaction terms became worse. This means that the approach used differs for each gene making it difficult to compare them. The challenges raised here suggested that expression is very difficult to predict with other factors but including these other factors would be difficult and plagued by multiple-testing, particularly comparing between them with the current synthetic lethal prediction method. This led to investigations into the simulation of synthetic lethality.
\fi

\FloatBarrier

\section{Replication in Stomach Cancer} \label{chapt3:stad_replication}

\textit{CDH1} is also important in stomach cancer biology as a driver tumour suppressor gene, including as a germline mutation in many cases of hereditary diffuse gastric cancer. The synthetic lethal analysis of genes and pathways (previously identified for TCGA breast cancer data) was replicated in TCGA stomach cancer. The accompanying data for \gls{SLIPT} analysis against \textit{CDH1} expression is provided in Appendix~\ref{appendix:stad_exprSL}.

While the sample size was lower for TCGA stomach cancer (particularly for mutations), these results serve to support the findings in breast cancer in an independent patient cohort and tissue samples. The molecular profiling, including RNA-Seq expression, were performed by TCGA using the sample procedures as for breast cancer and the findings reported here were performed used data analysis techniques identical to those presented previously. These procedures should ensure as close comparison as feasible across cancer types for those relevant to HDGC and recurrent \textit{CDH1} mutations.

The strongest \gls{SLIPT} genes for stomach cancer (shown in Table~\ref{tab:gene_stad_SL}) did not necessarily directly correspond to those observed in breast cancer (shown in Table~\ref{tab:gene_SL}). However, several gene functions were replicated in stomach cancer. Together, these gene candidates indicate widespread functions of \textit{CDH1} and strongly detectable synthetic lethality with many genes from a strategy that can be applied across cancer types. More specifically, the signalling genes included GPCR signalling genes, which was one of the most supported synthetic lethal pathways in breast cancer analysis, the experimental screen \citep{Telford2015}.%, and has many actionable drug targets which have been applied to other diseases.
These findings were further supported by the pathways over-represented in \gls{SLIPT} candidates from TCGA stomach cancer (shown in Table~\ref{tab:pathway_stad_exprSL}) which replicated the translational and immune pathways observed in TCGA breast cancer (shown in Table~\ref{tab:pathway_exprSL}) and further supported GCPR signalling pathways, including the class A/1 receptors. The extracellular matrix was also detected at the pathway level in stomach cancer, including elastic fibres, glycosylation, collagen, and integrin cell-surface interactions. 
While fewer pathways were supported by resampling for the intersection of \gls{SLIPT} and experimental screen \citep{Telford2015} candidate partners in stomach cancer than breast cancer, many of those detected (shown in Table~\ref{tab:pathway_perm_overlap_stad}) replicate those detected in breast cancer (shown in Table~\ref{tab:pathway_perm_overlap}). The pathways detected by both permutation and over-representation were more likely to be replicated across stomach and breast cancer than those detected by over-representation alone, supporting the use of this procedure to detect synthetic lethal pathways applicable across cancer types. The include G$_{\alpha s}$ signalling and elastic fibre formation as discussed for breast cancer (in Section~\ref{chapt3:compare_pathway_perm}).

\iffalse
\subsection{Synthetic Lethal Genes and Pathways} \label{chapt3:stad_SL_genes}

The strongest \gls{SLIPT} genes for stomach cancer (shown in Table~\ref{tab:gene_stad_SL}) did not necessarily directly correspond to those observed in breast cancer (shown in Table~\ref{tab:gene_SL}). However, several gene functions were replicated in stomach cancer. Cell membrane genes including \textit{EMP3}, \textit{GYPC},  \textit{LGALS1}, \textit{PRR24},  and \textit{FUNCD2} were among the strongest SL candidates. Similarly, cell signalling genes including \textit{PLEKHO1}, \textit{RARRES2}, \textit{VEGFB}, \textit{HSPB2}, and \textit{CREM} were detected in stomach cancers. It is notable that several of these genes (\textit{EMP3}, \textit{PLEKHO1}, and \textit{FUNCD2}) have a known role in cancer. Together these genes support the roles of \textit{CDH1} in cell membrane and signalling functions (of epithelial tissues) which are perturbed in both breast and stomach cancers.

The strongest mtSLIPT genes tested against \textit{CDH1} mutatoin for stomach cancer (shown in Table~\ref{tab:gene_stad_mtSL}) supported similar gene functions. Membrane and cell-adhesion genes including \textit{KFBP6},\textit{THY1},\textit{CLELC2B}, \textit{NISCH}, \textit{TSPAN1},and \textit{KCTD12} and signalling genes including \textit{ZEB2}, \textit{CCND2}, \textit{NEURL1B}, \textit{KFBP6}, and \textit{OGN} were detected. Similarly, these include cancer genes such as \textit{VIM},\textit{ZEB2},\textit{BCL2},\textit{THY1}, and \textit{RUNX1T1}. The mtSLIPT procedure also replicated several of the strongest candidates in breast cancer (shown in Table~\ref{tab:gene_mtSL}) such as \textit{NRIP2} and \textit{NISCH}.

Together, these gene candidates indicate widespread functions of \textit{CDH1} and strongly detectable synthetic lethality with many genes from a strategy that can be applied across cancer types. More specifically, the signalling genes included GPCR signalling genes (e.g., \textit{GNG11}, \textit{GNAI1}, \textit{DZIP1}, \textit{PTGFR}, and \textit{KCTD12}), a growth signalling pathway which was one of the most supported synthetic lethal pathways in breast cancer analysis, the experimental screen \citep{Telford2015}, and has many actionable drug targets which have been applied to other diseases.

These findings were further supported by the pathways over-represented in \gls{SLIPT} candidates from TCGA stomach cancer (shown in Table~\ref{tab:pathway_stad_exprSL}) which were replicated the translational and immune pathways observed in TCGA breast cancer (shown in Tabel~\ref{tab:pathway_exprSL}). Further support for GCPR signalling pathways including the class A/1 receptors. The extracellular matrix was also detected at the pathway level in stomach cancer \gls{SLIPT} candidates and replicated in mtSLIPT analysis for \textit{CDH1} mutation (shown in Table~\ref{tab:pathway_stad_mtSL}), including elastic fibres, glycosylation, collagen, and integrin cell-surface interactions. Thus there was strong evidence for the role of extracellular matrix pathways and the tumour microenvironment in \textit{CDH1} deficient stomach cancers, in addition to cell signalling and translation pathways important in tumour growth across breast and stomach cancer.




%%appendix

\FloatBarrier

\subsection{Synthetic Lethal Expression Profiles} \label{chapt3:stad_SL_clusters}

%The expression profiles of candidate synthetic lethal partners dtected by \gls{SLIPT} and mtSLIPT in stomach cancer were plotted against clinical characteristics as described for breast cancer data in Section~\ref{chapt3:exprSL_clusters} (shown in Figures~\ref{fig:slipt_expr_stad} and~\ref{fig:slipt_expr_stad_mtSL} respectively). As expected the majority of \textit{CDH1} mutant samples had low expression of \textit{CDH1} and were the diffuse type of stomach cancer.


\begin{figure*}[!ht]
%\begin{mdframed}
  \centering
  \resizebox{0.99 \textwidth}{!}{
    \includegraphics{CDH1_Heatmaps_Genes_Split_By_CDH1_z-trans_exprSL_cordistx_Pub_stad.png}
   }
    \caption[Synthetic lethal expression profiles of stomach samples]{\small \textbf{Synthetic lethal expression profiles of analysed samples.} Gene expression profile heatmap (correlation distance) of all samples (separated by the $\sfrac{1}{3}$ quantile of \textit{CDH1} expression) analysed in TCGA stomach cancer dataset for gene expression of 4,365 candidate partners of E-cadherin (\textit{CDH1}) from \gls{SLIPT} prediction (with significant FDR adjusted $p < 0.05$). Deeply clustered, inter-correlated genes form several main groups, each containing genes that were SL candidates or toxic in an siRNA screen \cite{Telford2015}. Clusters had different sample groups highly expressing the synthetic lethal candidates in \textit{CDH1} low samples, notably diffuse and \textit{CDH1} mutant samples have elevated expression in one or more distinct clusters, although there was less complexity and variation among candidate synthetic lethal partners than in breast data. \textit{CDH1} low samples also contained most of samples with \textit{CDH1} mutations.
   %This suggests that multiple targets may be needed to target \textit{CDH1} deficiency across genetic backgrounds and that combination therapy may be more effective. 
}
\label{fig:slipt_expr_stad}
%\end{mdframed}
\end{figure*}

%The \gls{SLIPT} partners of \textit{CDH1} exhibited similar clustering in staomch cancer to breast cancer, replicating the diverse roles of elevated partner genes in different clinical samples. Specifically (in Figure~\ref{fig:slipt_expr_stad}), the diffuse type stomach cancers had higher expression of the candidate synthetic lethal partners (where \textit{CDH1} has a role as a driver mutation), despite an unbiased clustering. This is consistent with compensating expression of synthetic lethal partners under loss of \textit{CDH1}, as suggested by \citet{Lu2015}. The pathway composition of gene clusters for stomach cancer (shown in Table~\ref{tab:pathway_clusters_stad}) was also highly concordant with breast cancer findings (shown in Table~\ref{tab:pathway_clusters}). These included replicated of translation (Cluster 1), immune functions (Cluster 2), G$_{\alpha s}$ signalling (Cluster 3), and further support for the roles of GPCRs and the extracellular matrix (Cluster 4) in the synthetic lethal partners and functions of \textit{CDH1}, replicated across stomach and breast cancers. Clusters 1 and 4, which had particularly high expression of \gls{SLIPT} candidate partner genes in the diffuse subtype, also had the most significant over-representation of pathways.

%There was less variation between the expression profiles of mtSLIPT partners of \textit{CDH1} in stomach cancer, although clusters were still detectable (as shown in Figure~\ref{fig:slipt_expr_stad_mtSL}). While the genes and pathways detected was lewss significant (due to lower sample size), the composition of clusters was further indicative for the roles of extracellular matrix (including elastic fibres), immune functions, and the cell signalling.

\FloatBarrier

\subsection{Comparison to Primary Screen} \label{chapt3:compare_SL_genes_stad}

The number of genes detected by both \gls{SLIPT} in TCGA stomach cancer data and siRNA in breast cell lines (shown in Figure~\ref{fig:Venn_allgenes_stad}) was also not a significant overlap (as observed for breast cancer in Figure~\ref{fig:Venn_allgenes}). This was particularly the case of mtSLIPT against \textit{CDH1} mutation in stomach cancer which detected very few genes (as shown in Figure~\ref{fig:Venn_allgenes_stad_mtSL}) due to low sample size and mutation frequency.

This smaller overlap can also be attributed to the tissue-specific differences between the stomach cancers and the breast cells used for the experimental model \citep{Chen2014}. Nevertheless, many genes were detected across \gls{SLIPT} in stomach cancers and the experimental screen \citep{Telford2015} and the pathways detected were consistent with prior observations in breast cancer. Despite differences in the specific genes detected, the functions of \textit{CDH1} were conserved across epithetial cancers in different tissues and synthetic lethal inhibition of interacting pathways may be effective against molecular targets such as \textit{CDH1} inactivation across tissue types.

However, the pathway composition of \gls{SLIPT}-specific genes and those replicated with the siRNA primary screen \citep{Telford2015} were highly concordant between the pathways identified by \gls{SLIPT} in TCGA stomach cancer (shown in Table~\ref{tab:Venn_over-representation_stad}) and pathways previously identified in TCGA breast cancer (shown in Table~\ref{tab:Venn_over-representation}). In both cases, translation and immune pathways were highly over-represented in \gls{SLIPT}-specific genes, which we would not expect to be detected by siRNA screening in cell lines, as discussed in Section~\ref{chapt3:compare_pathway}. In addition, the extracellular matrix was supported by in stomach cancer. While the pathways identified by specifically by \gls{SLIPT} in stomach cancer or siRNA screening were similar to those observed for breast cancer (in Table~\ref{tab:Venn_over-representation}), the pathways over-represented in the intersection for stomach cancer \gls{SLIPT} candidates and the siRNA primary screen \citep{Telford2015} also had a clear over-representation of signalling pathways, although they differed from those observed in breast cancer \gls{SLIPT} candidates. GPCR signalling was supported in genes detected in both TCGA stomach cancer and screening, including G$_{\alpha q}$, G$_{\alpha s}$, serotonin receptors, and class A signalling (shown in more detail in Table~\ref{tab:pathway_perm_overlap_stad}). In addition MAPK and NOTCH signalling pathways were detected. These replicate the findings in breast cancer and show consistent detection of signalling pathways in stomach cancer despite less genes being detected by \gls{SLIPT} and patient samples differing from the tissue in which the experiments were conducted.

Similarly, the \gls{SLIPT}-specific gene candidates against \textit{CDH1} mutation (shown in Table~\ref{tab:Venn_over-representation_stad_mtSL}) replicated pathways observed in breast cancer (shown in Table~\ref{tab:Venn_over-representation_mtSL}), despite a lower number of genes detected. In particular, the extracellular matrix and elastic fibres were over-represented. While the number of genes overlapping with the siRNA was too low to be amenable to pathway analysis, there is further indication that members of these genes replicated across mutation \gls{SLIPT} analyses include cell-membrane, elastic fibre, and GPCR signalling genes. 

\FloatBarrier

\subsubsection{Resampling Analysis}  \label{chapt3:compare_pathway_perm_stad_SL}

Similarly, resampling for \gls{SLIPT} specific candidates (shown in Tables~\ref{tab:pathway_perm_stad} and~\ref{tab:pathway_perm_stad_mtSL}) replicated many of the most highly over-represented pathways in stomach cancer. These include translational, immune, GPCR signalling, and elastic fibres, consistent with previous analyses in breast cancer (shown in Tables~\ref{tab:pathway_perm} and~\ref{tab:pathway_perm_mtSL}).

While fewer pathways were supported by resampling for the intersection of \gls{SLIPT} and experimental screen \citep{Telford2015} candidate partners in stomach cancer than breast cancer, many of those detected (shown in Table~\ref{tab:pathway_perm_overlap_stad}) replicate those detected in breast cancer (shown in Tables~\ref{tab:pathway_perm_overlap} and~\ref{tab:pathway_perm_overlap_mtSL}). The pathways detected by both permutation and over-representation were more likely to be replicated across stomach and breast cancer than those detected by over-representation alone, supporting the use of this procedure to detect synthetic lethal pathways applicable across cancer types. The include G$_{\alpha s}$ signalling and elastic fibre formation as discussed for breast cancer (in Section~\ref{chapt3:compare_pathway_perm}).

While many pathways were detected by resampling for mtSLIPT against \textit{CDH1} mutation in stomach cancer (shown in Table~\ref{tab:pathway_perm_overlap_stad_mtSL}), there were not enough genes detected by both mtSLIPT and the siRNA primary screen to determine over-represented pathways. Therefore this may be due to small numbers of genes which does not constitute support for pathway composition. However, this under-powered analysis does not preclude the replicated synthetic lethal pathways detected across \gls{SLIPT} expression analyses in TCGA breast and stomach cancer data with an accompanying siRNA primary screen \citep{Telford2015}. Rather this further supports the use of \gls{SLIPT} to test against low expression of query genes as measure of gene inactivation to avoid this issue, despite mutation (which often produces similar results) being more indicative of complete gene inactivation.

\FloatBarrier

\subsection{Metagene Analysis} \label{chapt3:metagene_stad_SL}

Metagene analysis (as conducted in Section~\ref{chapt3:metagene_SL}) was also performed for TCGA stomach cancer expression data, using Reactome pathways. These results (as shown in Table~\ref{tab:metagene_stad_SL}) provided further support for signalling and extracellular processes as synthetic lethal pathways across stomach and breast cancer. Namely, cell-cell communication, VEGF signalling, and various GPCR pathways were detected.  

Signalling and immune pathways were also supported by mtSLIPT analysis of metagene pathway expression against \textit{CDH1} mutation, as shown in Table~\ref{tab:metagene_stad_mtSL}. However, these results were generally less statistically significant than expression analyses. Signalling pathways detected as synthetic lethal metagenes include prostacyclin, SCF-KIT, ERK, MAPK, NGF, VEGF, and PI3K/AKT. The innate immune response, the inflammasome, and integrin signalling were also implicated to be synthetic lethal with \textit{CDH1 mutations}. Cell surface interactions, cholesterol biosynthesis, and platelet homeostasis also support the role of extracellular processes in proliferation of \textit{CDH1} deficient cancers and interactions of \textit{CDH1} with the extracellular environment that was not tested in the cell line experimental screen.

%%appendix
%\label{tab:metagene_stad_mtSL}
\fi

\FloatBarrier

\iffalse
\section{Global Synthetic Lethality}
%[include?]

Global levels of synthetic lethality were analysed to address concerns raised by the high numbers of synthetic lethal candidates for \textit{CDH1}. The \gls{SLIPT} procedure (as described in Section~\ref{methods:SLIPT}) was performed with each possible query gene from the TCGA breast cancer RNA-Seq dataset. Due to the computational demands of this procedure, it was performed on the New Zealand eScience Infrastructure Intel Pan supercomputer (as described in Section~\ref{methods:HPC}).

The observed number of \gls{SLIPT} appears to be typical for most genes in the TCGA breast RNA- Seq dataset as shown in Figure~\ref{fig:global_SL}. This figure was actually lower than the majority (95\%) of genes tested, although \textit{CDH1} was ranked higher for a similar in \gls{SLIPT} analysis of TCGA stomach cancer data, shown in Figure~\ref{fig:global_SL_stad}. The differences in sample size make these analyses difficult to compare but (in either case), the number of partners detected for \textit{CDH1} is not unexpected, eeven when adjust for multiple comparisons across candidate partners.

\begin{figure*}[!ht]
%\begin{mdframed}
  \begin{center}
  \resizebox{0.75 \textwidth}{!}{
    \includegraphics{MostSL_Summary_CDH1_FDR.pdf}
   }
   \end{center}
   \caption[Synthetic lethal partners across query genes]{\small \textbf{Synthetic lethal partners across query genes.} Global synthetic lethal pairs were examined across the genome in TCGA breast expression data by applying \gls{SLIPT} across query genes. The high number of predicted partners for \textit{CDH1} was typical for a human gene and lower than many other genes.
   }
\label{fig:global_SL}
%\end{mdframed}
\end{figure*}

The number of detected candidates reported here is higher than in Figures~\ref{fig:Venn_allgenes} and~\ref{fig:Venn_allgenes_stad} because these exlcuded genes not tested by the siRNA primary screen \citep{Telford2015} for comparison with it. For an statistically rigorous measure of global synthetic lethality, multiple comparison procedures would need to be performed for all pairs of genes tested. However, only partner genes for each query \gls{SLIPT} analysis were performed for the purposes of comparing the number of partners predicted with those observed for \textit{CDH1} throughout this thesis.


\FloatBarrier

\subsection{Hub Genes}

The genes with the most synthetic lethal interactions by this \gls{SLIPT} analysis are the ``hub'' genes of a synthetic lethal network. These genes with the highest number of candidate partners detected by \gls{SLIPT} in TCGA breast cancer expression data are summarised in Table~\ref{tab:gene_mostSL}.  These include several genes involved in cellular signalling such as \textit{TGFBR2}, \textit{PDGFRA}, \textit{FAM126A}, \textit{KCTD12}, \textit{MAML2}, and \textit{CAV1}. Gene regulation including chromatin, DNA, and RNA bindings genes were also observed as hub genes such as \textit{CELF2}, \textit{PLAGL1}, \textit{TSHZ2}, \textit{FOXO1}, and \textit{SVEP1}. Genes involved in the cellular membrane such as \textit{ANXA1} and \textit{FAM171A1} were also observed in addition to genes specifically implicated in cell adhesion and tight junctions such as \textit{TNS1}, \textit{BOC}, \textit{AMOTL1}, \textit{FAT4}, and \textit{EPB41L2}.

\begin{table*}[!ht]
\caption{Query synthetic lethal genes with the most SLIPT partners}
\label{tab:gene_mostSL}
\centering
\resizebox{0.8 \textwidth}{!}{
\begin{threeparttable}
\begin{tabular}{>{\em}sl^c^c^c^c^c}
\rowstyle{\bfseries}
  \em{Gene} & Direction & raw p-value & p-value (FDR) & \gls{SLIPT} raw p-value & \gls{SLIPT} (FDR) \\ 
  \hline
  \rowcolor{black!10}
  TGFBR2 & 8134 & 17982 & 17973 & 8007 & 8006 \\ 
  \rowcolor{black!5}
  A2M & 8571 & 17605 & 17583 & 8345 & 8339 \\ 
  \rowcolor{black!10}
  TNS1 & 8019 & 17949 & 17934 & 7874 & 7873 \\ 
  \rowcolor{black!5}
  PROS1 & 8539 & 17668 & 17642 & 8317 & 8310 \\ 
  \rowcolor{black!10}
  ANXA1 & 9085 & 17330 & 17302 & 8689 & 8682 \\ 
  \rowcolor{black!5}
  CELF2 & 8665 & 17406 & 17368 & 8370 & 8355 \\ 
  \rowcolor{black!10}
  BOC & 8694 & 17371 & 17348 & 8384 & 8381 \\ 
  \rowcolor{black!5}
  PLAGL1 & 8792 & 17361 & 17327 & 8448 & 8436 \\ 
  \rowcolor{black!10}
  PDGFRA & 8296 & 17650 & 17621 & 8095 & 8087 \\ 
  \rowcolor{black!5}
  FAM171A1 & 8874 & 17560 & 17533 & 8567 & 8562 \\ 
  \rowcolor{black!10}
  FAM126A & 8510 & 17383 & 17356 & 8184 & 8178 \\ 
  \rowcolor{black!5}
  TSHZ2 & 7942 & 17983 & 17976 & 7787 & 7786 \\ 
  \rowcolor{black!10}
  KCTD12 & 8366 & 17651 & 17621 & 8115 & 8108 \\ 
  \rowcolor{black!5}
  MAML2 & 8336 & 17537 & 17503 & 8069 & 8061 \\ 
  \rowcolor{black!10}
  FOXO1 & 8027 & 17753 & 17737 & 7840 & 7836 \\ 
  \rowcolor{black!5}
  AMOTL1 & 8425 & 17388 & 17347 & 8147 & 8139 \\ 
  \rowcolor{black!10}
  FAT4 & 8111 & 17750 & 17732 & 7925 & 7919 \\ 
  \rowcolor{black!5}
  CAV1 & 8645 & 17491 & 17464 & 8342 & 8331 \\ 
  \rowcolor{black!10}
  SVEP1 & 7945 & 17859 & 17842 & 7791 & 7784 \\ 
  \rowcolor{black!5}
  EPB41L2 & 8415 & 17327 & 17296 & 8097 & 8092 \\ 
  \hline
\end{tabular}
\begin{tablenotes}
\raggedright \small
Genes with the most candidate SL partners \gls{SLIPT} in TCGA breast expression data with the number of partner genes predicted by direction criteria and $\chi^2$ testing separately and combined as a \gls{SLIPT} analysis. Where specified, the p-values for the $\chi^2$ test were adjusted for multiple tests (FDR).
\end{tablenotes}
\end{threeparttable}
}
\end{table*}

Genes involved in adhesion and tight junctions were also hub genes in stomach cancer (shown in Table~\ref{tab:gene_mostSL_stad}) such as \textit{HEG1}, \textit{FAT4}, \textit{NFASC}, \textit{LAMA4}, \textit{LAMC1}, \textit{TNS1}, and \textit{AMOTL1}. These also included cytoskeletal genes such as \textit{ANK2}, \textit{TTC28}, and \textit{MACF1}. Cancer genes were also among hub genes across breast and stomach cancer such as \textit{BOC}, \textit{FAT4}, and \textit{MRVI1}. 

It is therefore unsurprising that signalling and regulatory genes have been detected throughout this thesis. Not only are they suitable targets for anti-cancer therapy, they are also highly interacting genes themselves and so it is plausible that their interactions would be detectable by \gls{SLIPT}. This is consistent with the established role of abberant signalling and gene regulation in proliferation and survival of tumours and the importance of these pathways in development with highly redundant functions across many genes under complex regulation. These are also highly amenable to detection by \gls{SLIPT} analysis of expression data since their functions are dynamically regulated with corresponding changes in expression.

Cytoskeletal, membrane bound, and extracellular matrix genes are also among highly interacting synthetic lethal hubs, including focal adhesion, tight junctions, microtubules, and fibronectin. These support the use of synthetic lethal interactions to target \textit{CDH1}, as a tumour suppressor gene involved in these functions. Cellular structure and cell-cell interactions are thus important functions with highly redundant genes for which there are many feasible synthetic lethal interactions by which to understand regulation of cellular functions. These functions may also be exploited as vulnerabilities in cancer as they are frequently disruped in cancers, including HDGC where loss of \textit{CDH1} is a driver of cancer proliferation and malignancy.  


\FloatBarrier

\subsection{Hub Pathways}

Pathways over-represented among TCGA breast cancer hub genes (as shown in Table~\ref{tab:pathway_mostSL}) particularly support the importance of signalling pathways, such as the PI3K/AKT pathway, as synthetic lethal hubs. The highly redundant natures of cell-cell interaction and the extracellular matrix functions was also further supported.


\begin{table*}[!ht]
\caption{Pathways for genes with the most SLIPT partners}
\label{tab:pathway_mostSL}
\centering
\resizebox{1 \textwidth}{!}{
\begin{threeparttable}
\begin{tabular}{lcccc}
  \cellcolor{white} \textbf{Pathways Over-represented} & \textbf{Pathway Size} & \textbf{SL Genes} & \textbf{p-value} & \textbf{p-value (FDR)} \\
  \hline
  \rowcolor{black!10}
  Constitutive Signalling by Aberrant PI3K in Cancer &  56 &  10 & $8.4 \times 10^{-16}$ & $8.7 \times 10^{-13}$ \\ 
  \rowcolor{black!5}
  PI3K/AKT Signalling in Cancer &  78 &  11 & $2.1 \times 10^{-14}$ & $1.1 \times 10^{-11}$ \\ 
  \rowcolor{black!10}
  Role of LAT2/NTAL/LAB on calcium mobilization &  96 &  12 & $7.7 \times 10^{-14}$ & $2.2 \times 10^{-11}$ \\ 
  \rowcolor{black!5}
  Complement cascade &  33 &   7 & $1.2 \times 10^{-13}$ & $2.2 \times 10^{-11}$ \\ 
  \rowcolor{black!10}
  Cell surface interactions at the vascular wall &  99 &  12 & $1.6 \times 10^{-13}$ & $2.2 \times 10^{-11}$ \\ 
  \rowcolor{black!5}
  PI3K events in ERBB4 signalling &  87 &  11 & $2.6 \times 10^{-13}$ & $2.2 \times 10^{-11}$ \\ 
  \rowcolor{black!10}
  PIP3 activates AKT signalling &  87 &  11 & $2.6 \times 10^{-13}$ & $2.2 \times 10^{-11}$ \\ 
  \rowcolor{black!5}
  PI3K events in ERBB2 signalling &  87 &  11 & $2.6 \times 10^{-13}$ & $2.2 \times 10^{-11}$ \\ 
  \rowcolor{black!10}
  PI-3K cascade:FGFR1 &  87 &  11 & $2.6 \times 10^{-13}$ & $2.2 \times 10^{-11}$ \\ 
  \rowcolor{black!5}
  PI-3K cascade:FGFR2 &  87 &  11 & $2.6 \times 10^{-13}$ & $2.2 \times 10^{-11}$ \\ 
  \rowcolor{black!10}
  PI-3K cascade:FGFR3 &  87 &  11 & $2.6 \times 10^{-13}$ & $2.2 \times 10^{-11}$ \\ 
  \rowcolor{black!5}
  PI-3K cascade:FGFR4 &  87 &  11 & $2.6 \times 10^{-13}$ & $2.2 \times 10^{-11}$ \\ 
  \rowcolor{black!10}
  Extracellular matrix organization & 238 &  22 & $4.7 \times 10^{-13}$ & $3.6 \times 10^{-11}$ \\ 
  \rowcolor{black!5}
  Muscle contraction &  62 &   9 & $4.9 \times 10^{-13}$ & $3.6 \times 10^{-11}$ \\ 
  \rowcolor{black!10}
  PI3K/AKT activation &  90 &  11 & $5.5 \times 10^{-13}$ & $3.8 \times 10^{-11}$ \\ 
  \rowcolor{black!5}
  GAB1 signalosome &  91 &  11 & $7.1 \times 10^{-13}$ & $4.6 \times 10^{-11}$ \\ 
  \rowcolor{black!10}
  Smooth Muscle Contraction &  28 &   6 & $2.4 \times 10^{-12}$ & $1.5 \times 10^{-10}$ \\ 
  \rowcolor{black!5}
  Response to elevated platelet cytosolic Ca$^{2+}$ &  82 &  10 & $2.6 \times 10^{-12}$ & $1.5 \times 10^{-10}$ \\ 
  \rowcolor{black!10}
  Signalling by SCF-KIT & 126 &  13 & $3.0 \times 10^{-12}$ & $1.6 \times 10^{-10}$ \\ 
  \rowcolor{black!5}
  Signalling by FGFR & 143 &  14 & $5.0 \times 10^{-12}$ & $2.2 \times 10^{-10}$ \\ 
   \hline
\end{tabular}
\begin{tablenotes}
\raggedright \small
Gene set over-representation analysis (hypergeometric test) for Reactome pathways in the top 500 ``hub'' genes with the most candidate synthetic lethal partners by \gls{SLIPT} analysis of TCGA breast expression data.
\end{tablenotes}
\end{threeparttable}
}
\end{table*}

Pathway over-representation for synthetic lethal hub genes was replicated in TCGA stomach cancer expression data. However, these pathways differ considerably from breast cancer, as shown in Table~\ref{tab:pathway_mostSL_stad}. Cell-cell interactions and extracellular matrix pathways, including elastic fibres, were also among the hub genes for stomach cancer. The signalling pathways differ as expected in a different tissue type, although BMP and PAK signalling were detected as hub gene functions.
\fi

\FloatBarrier

\iffalse
\section{Replication in the Cancer Cell Line Encyclopaedia} \label{chapt3:CCLE}

\FloatBarrier

\begin{table*}[!b]
\caption{Pathways for \textit{CDH1} partners from SLIPT in CCLE}
\label{tab:pathway_ccle_exprSL}
\centering
\resizebox{1 \textwidth}{!}{
\begin{threeparttable}
\begin{tabular}{lccc}
  \hline
  \cellcolor{white} \textbf{Pathways Over-represented} & \textbf{Pathway Size} & \textbf{SL Genes} & \textbf{p-value (FDR)} \\
  \hline
  \rowcolor{black!10}
  Cell Cycle & 442 & 207 & $1.2 \times 10^{-215}$ \\ 
  \rowcolor{black!5}
  Cell Cycle, Mitotic & 365 & 180 & $2.9 \times 10^{-209}$ \\ 
  \rowcolor{black!10}
  Signalling by Rho GTPases & 311 & 136 & $9.4 \times 10^{-156}$ \\ 
  \rowcolor{black!5}
  M Phase & 212 & 104 & $8.8 \times 10^{-145}$ \\ 
  \rowcolor{black!10}
  Infectious disease & 289 & 123 & $1.3 \times 10^{-142}$ \\ 
  \rowcolor{black!5}
  RHO GTPase Effectors & 207 &  98 & $5.3 \times 10^{-135}$ \\ 
  \rowcolor{black!10}
  HIV Infection & 200 &  94 & $2 \times 10^{-130}$ \\ 
  \rowcolor{black!5}
  Separation of Sister Chromatids & 140 &  77 & $5.6 \times 10^{-128}$ \\ 
  \rowcolor{black!10}
  Organelle biogenesis and maintenance & 258 & 107 & $1.4 \times 10^{-127}$ \\ 
  \rowcolor{black!5}
  Chromatin modifying enzymes & 181 &  87 & $4.7 \times 10^{-126}$ \\ 
  \rowcolor{black!10}
  Chromatin organization & 181 &  87 & $4.7 \times 10^{-126}$ \\ 
  \rowcolor{black!5}
  Mitotic Metaphase and Anaphase & 149 &  78 & $1.2 \times 10^{-124}$ \\ 
  \rowcolor{black!10}
  Mitotic Anaphase & 148 &  77 & $6.3 \times 10^{-123}$ \\ 
  \rowcolor{black!5}
  Developmental Biology & 421 & 142 & $1.6 \times 10^{-121}$ \\ 
  \rowcolor{black!10}
  RHO GTPases Activate Formins &  94 &  60 & $5.3 \times 10^{-118}$ \\ 
  \rowcolor{black!5}
  Mitotic Prometaphase &  93 &  59 & $5.4 \times 10^{-116}$ \\ 
  \rowcolor{black!10}
  Hemostasis & 421 & 138 & $7.2 \times 10^{-116}$ \\ 
  \rowcolor{black!5}
  Adaptive Immune System & 397 & 132 & $3.2 \times 10^{-115}$ \\ 
  \rowcolor{black!10}
  Assembly of the primary cilium & 143 &  72 & $2.4 \times 10^{-114}$ \\ 
  \rowcolor{black!5}
  Transcription & 133 &  68 & $6.2 \times 10^{-111}$ \\ 
   \hline
\end{tabular}
\begin{tablenotes}
\raggedright \small
Gene set over-representation analysis (hypergeometric test) for Reactome pathways in \gls{SLIPT} partners for \textit{CDH1}.
\end{tablenotes}
\end{threeparttable}
}
\end{table*}

As breast cancer cell lines are the experimental system in which many cancer genetics and drug targets are investigated, these were analysed in addition to patient samples from TCGA. The cancer cell line encyclopaedia (CCLE) is a resource for genomics profiles across a range of cell lines. These have also been used to generate synthetic lethal candidates for comparison to those in experimental screen and predictions from TCGA expression data.

The cancer cell line encyclopaedia provides further support for synthetic lethal genes and pathways that may be applicable across cell types and reproducible in experimental systems. In contrast to the homogeneous pooled cell samples of patients,  the cell lines provide a genetically homogeneous cell population in which to examine molecular functions and as a preclinical model of cancerous disease. The complete set of 1037 cell lines was tested for synthetic lethality across tissues, in addition to the 59 breast cell lines and 38 stomach cell lines being tested separately for partners of \textit{CDH1}. Synthetic lethal genes were detected by \gls{SLIPT} (as described in Section~\ref{methods:SLIPT}) and over-represented synthetic lethal Reactome pathways (as described in Section~\ref{methods:enrichment}). 

Synthetic lethal gene candidates were detectable by \gls{SLIPT} across each of these sample sets of cells lines (as shown in Tables~\ref{tab:gene_ccle_SL}\nobreakdash--\ref{tab:gene_ccle_stad_SL}. However, these were most highly significant across the samples in the CCLE expression dataset (as shown in Table~\ref{tab:gene_ccle_SL}) and included genes detected in prior analyses such as \textit{VIM}, \textit{ZEB2}, \textit{EMP3}. Pathways were also highly over-represented among synthetic lethal candidates for the full CCLE dataset (as shown in Table~\ref{tab:pathway_ccle_exprSL}) including Rho GTPase (GPCRs), immmune, and gene regulation (chromatin and transcription). This is unexpected since immune pathways would not be expected to be detectable in isolated cell lines, although this could be attributed to cytokine and integrin signalling occuring the cancer cells in addition to interactions with immune cells in the tumour microenvironment (which could not be distinguished in patient samples). Cell cycle and mitosis were among the highest synthetic lethal pathways across cell lines supporting \textit{CDH1} deficient cells having abberant cell signalling and consequences for proliferation such as cancer cells. However, cell cycle genes were not as strongly supported in TCGA patient samples or the siRNA screen \citep{Telford2015} and they may not be applicable to epithelial tissues such as breast or stomach cancer or amenable to selective inhibition in experimental models.   

\begin{table*}[!tb]
\caption{Pathways for \textit{CDH1} partners from SLIPT in breast CCLE}
\label{tab:pathway_ccle_brca_exprSL}
\centering
\resizebox{1 \textwidth}{!}{
\begin{threeparttable}
\begin{tabular}{lccc}
  \hline
  \cellcolor{white} \textbf{Pathways Over-represented} & \textbf{Pathway Size} & \textbf{SL Genes} & \textbf{p-value (FDR)} \\
  \hline
  \rowcolor{black!10}
  Cell junction organization &  71 &   5 & 0.006 \\ 
  \rowcolor{black!5}
  Adherens junctions interactions &  29 &   3 & 0.006 \\ 
  \rowcolor{black!10}
  Dermatan sulfate biosynthesis &  11 &   2 & 0.006 \\ 
  \rowcolor{black!5}
  Non-integrin membrane-ECM interactions &  52 &   4 & 0.006 \\ 
  \rowcolor{black!10}
  Regulation of pyruvate dehydrogenase (PDH) complex &  12 &   2 & 0.0069 \\ 
  \rowcolor{black!5}
  Cell-extracellular matrix interactions &  17 &   2 & 0.021 \\ 
  \rowcolor{black!10}
  Pyruvate metabolism &  17 &   2 & 0.021 \\ 
  \rowcolor{black!5}
  Cell-cell junction organization &  46 &   3 & 0.039 \\ 
  \rowcolor{black!10}
  Synthesis of substrates in N-glycan biosythesis &  50 &   3 & 0.057 \\ 
  \rowcolor{black!5}
  Detoxification of Reactive Oxygen Species &  26 &   2 & 0.082 \\ 
  \rowcolor{black!10}
  Keratan sulfate biosynthesis &  28 &   2 & 0.092 \\ 
  \rowcolor{black!5}
  Laminin interactions &  28 &   2 & 0.092 \\ 
  \rowcolor{black!10}
  Cell-Cell communication & 118 &   5 & 0.12 \\ 
  \rowcolor{black!5}
  Keratan sulfate/keratin metabolism &  32 &   2 & 0.12 \\ 
  \rowcolor{black!10}
  Opioid Signalling &  63 &   3 & 0.12 \\ 
  \rowcolor{black!5}
   \begin{tabular}[c]{@{}l@{}}Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide) \\ and transfer to a nascent protein \end{tabular} &  63 &   3 & 0.12 \\ 
  \rowcolor{black!10}
  Intraflagellar transport &  34 &   2 & 0.14 \\ 
  \rowcolor{black!5}
  Signalling by Retinoic Acid &  36 &   2 & 0.16 \\ 
  \rowcolor{black!10}
  Pyruvate metabolism and Citric Acid (TCA) cycle &  36 &   2 & 0.16 \\ 
  \rowcolor{black!5}
  Nef mediated downregulation of MHC class I complex cell surface expression &  10 &   1 & 0.22 \\ 
  \hline
\end{tabular}
\begin{tablenotes}
\raggedright \small
Gene set over-representation analysis (hypergeometric test) for Reactome pathways in \gls{SLIPT} partners for \textit{CDH1}.
\end{tablenotes}
\end{threeparttable}
}
\end{table*}


Synthetic lethal pathways specific to \gls{SLIPT} candidates from breast cell lines (as shown in Table~\ref{tab:pathway_ccle_brca_exprSL}) were more consistent with previous obervations, particularly the established role of E-cadherin in cell junctions and the Adherens complex. However, the number of \gls{SLIPT} candidate genes detected in stomach cell lines was insufficient to replicate the findings in breast cell lines to TCGA patient samples. However, \gls{SLIPT} candidates across breast and stomach CCLE cell lines were over-represented (as shown in Table~\ref{tab:pathway_ccle_breast_stad_exprSL}) for similar pathways to breast cell lines with additional support for extracellular matrix pathways including elastic fibres which were replicated with resampling across breast and stomach TCGA analyses and the primary siRNA screen \citet{Telford2015}
\fi

\FloatBarrier

\section{Discussion}

\subsection{Strengths of the SLIPT Methodology}

Synthetic lethal discovery  with \gls{SLIPT} used established statistical procedures to identify putative partner genes from gene expression data. Such use of the $\chi^2$-value is amenable to pathway or permutation analyses and could feasibly be applied to other disease gene or pair-wise across the genome, although genome-wide approaches were unable to find informative candidate genes for E-cadherin \citep{Lu2015}. Synthetic lethal discovery in cancer has focused on genes with severe cellular mutant phenotypes, such as essential genes or the oncogenes \textit{TP53} and \textit{AKT} \citep{Tiong2014, Lu2015, Wang2013}, with other cancer genes, such as \textit{CDH1}, requiring more focused investigations. Prior computational approaches for synthetic lethal discovery, in cancer, vary widely \citep{Tiong2014, Jerby2014, Lu2015, Wappett2016}. There is no consensus as to which approach is more appropriate, and the methods are difficult to compare, as they either do not have a released code implementation or do not make predictions solely from normalised expression data.

However, the query-based approach demonstrated by \gls{SLIPT} analysis is suitable for wider application on expression data and for augmenting experimental studies such as high-throughput screens. This approach has identified biologically plausible synthetic lethal pathways for \textit{CDH1}, triaged candidates from experimental screening \citep{Telford2015}, and replicates genes and pathways across breast and stomach cancer datasets. In addition, \gls{SLIPT} avoids critical assumptions underlying the design of some approaches such as co-expression of synthetic candidates or that interacting gene pairs will have known (annotated) similarities in function.

The DAISY methodology \cite{Jerby2014}, which took a similar query-based approach with the tumour suppressor \textit{VHL}, has been critiqued for being too stringent \citep{Lu2015} which impedes pathway analysis. Since functional redundancy does not require genes to be expressed at the same time, the \gls{SLIPT} approach does not assume co-expression of synthetic lethal genes which may enrich for synthetic lethal genes in established coregulated pathways. Rather, the interpretation of synthetic lethality for \gls{SLIPT} was similar to other computational methods based on `co-loss under-represent\-at\-ion', `compensation', or `simultaneous differential expression' \citep{Tiong2014, Lu2015, Wang2013}.

Genomics analyses are prone to false-positives and require statistical caution, particularly where working with gene-pairs scale sup the number of multiple tests drastically, at the expense of statistical power.  Experimental screens for synthetic lethality are also error-prone \citep{Lu2015, Fece2015, Lord2014}, especially with false-positives, raising the need for understanding the expected behaviour and number of functional relationships and genetic interactions in the genome, or in discovery of synthetic lethal partners of a particular query gene. Thus analyses throughout this thesis have focused on querying for partners of a particular gene of interest. Statistical modelling and simulations (in Section~\ref{chapt2:simulation_2015} and Chapter~\ref{chap:simulation}) will further support the design decisions underlying \gls{SLIPT} analysis and it's strengths over other approaches.

\subsection{Synthetic Lethal Pathways for E-cadherin}

Specific genes were difficult to replicate across experiments. This is consistent with gene expression profiles for synthetic lethal partners reflecting the complexity of biological pathways which are subject to higher-order interactions and do not consistently compensate for loss of gene function across all samples \citep{Kelly2013, Jerby2014, Lu2015}. The predicted synthetic lethal partners of \textit{CDH1} (with FDR correction) were investigated with gene expression profiles and clinical variables to find relationships in gene expression, gene function, and clinical characteristics. The large number of genes detected indicates that synthetic lethal detection is potentially error-prone, and that identifying genes relevant for clinical application will be difficult without a supporting biological pathway rationale. As such, investigations into the genes identified by \gls{SLIPT}, the correlation structure between them, and those which were validated by experimental screening \citep{Telford2015} focused at the pathway level throughout this Chapter. Similarly, comparisons across analyses were largely made at the pathway level, including comparisons between expression and mutation, breast and stomach \gls{TCGA} datasets.%, and patient sample data with cell line expression profiles.

Potential synthetic lethal partners of \textit{CDH1} identified by \gls{SLIPT} had many distinct functions, with each gene cluster highly expressed in different patient subgroups (Figure~\ref{fig:slipt_expr}). The expression profiles of the SL partners of \textit{CDH1} predicted from \gls{TCGA} breast cancer RNA-Seq data (expected to have compensating high or stable expression) and their corresponding functional enrichment found  in subgroups of genes, particularly among \textit{CDH1} low breast tumours.  Ductal breast cancers showed higher expression of synthetic lethal partners suggesting treatment would be more effective in this tumour subtype.  However, there was consistently low expression of SL partners in estrogen receptor negative tumours, although this is independent of tumour stage and consistent with poor prognosis in these patients and could inform other treatment strategies or prevent ineffective treatment further impacting quality of life in these patients.  These results suggest that synthetic lethal partner expression varies between patients; that these different tumour classes would react differently to the same treatment; that treatment of different pathways and combinations in different patients is the most effective approach to target genes compensating for \textit{CDH1} gene loss; and that the expression of synthetic partners could be a clinically important biomarker.  

The pathways that synthetic lethal partners of \textit{CDH1} identified by \gls{SLIPT} were involved in a diverse range of biological functions and differed to those detected experimentally. This discrepancy may be accounted for by gene expression analyses detecting both synthetic lethal partners, as screened for experimentally by \citet{Telford2015}, and their downstream targets (not detected by siRNA), capturing the wider pathways and mechanisms involved in synthetic lethality with \textit{CDH1} inactivation. In particular, GPCR phosphorylation cascades (which regulate gene expression and translation in cancers \citep{Gao2015}) were predicted to be synthetic lethal with \textit{CDH1}. The predicted synthetic lethal partners occurred across functionally distinct pathways, including characterised functions of \textit{CDH1}. The most consistently supported pathways included elastic fibres in the extracelullar matrix, GPCR signalling, and translation presenting vulnerabilities for \textit{CDH1} deficient cancer cells from extracellular stimuli to the core growth mechanisms of a cell.

This diversity in synthetic lethal functions is consistent with the wide ranging role of \textit{CDH1} in cell-cell adhesion, cell signalling, and the cytoskeletal structure of epithelial tissues. Pathway structure may be relevant to identifying potential drug targets from gene expression signatures, indicating downstream effector genes and mechanisms leading to cell inviability. Identification of distinct synthetic lethal gene clusters may further lead to the elucidation of drug resistance mechanisms. While these pathways are indicative of the main functions of E-cadherin and synthetic lethal partners, it remains to identify the genes within these pathways that are the most actionable or supported across \gls{SLIPT} analysis in patient samples and detected by experiments in preclinical models \citep{Chen2014, Telford2015}.  The specific genes within key pathways will be be discussed in Chapter~\ref{chap:Pathways}, along with further investigations into their relation to pathway structure.  While these are important clinical implications, the synthetic lethal predictions lack enough confidence for direct translation into pre-clinical models or clinical applications leading to a need for statistical modelling and simulation of synthetic lethality in genomics expression data.

These synthetic lethal pathways have potential clinical implications, particularly those supported in pre-clinical models and in patient expression data. However, further validation of gene candidates will be necessary to ensure that these are able to reproduced in further pre-clinical studies, they are applicable to tumours \textit{in vivo}, and that effective inhibitory agents can be repurposed or designed against them.

\subsection{Replication and Validation}

\subsubsection{Integration with siRNA Screening}

The pathway composition across computational and experimental synthetic lethal candidates was informative with over-represent\-ation (Table~\ref{tab:Venn_over-representation}) and supported by resampling analysis (Table~\ref{tab:pathway_perm_overlap}), despite a modest intersection of genes between them (Figure~\ref{fig:Venn_allgenes}). Either approach may be significant for a pathway in this intersection without being supported by the other: resampling analysis may support pathways that were not over-represent\-ed due to small effect sizes, thus both tests are required for a candidate pathway.

The pathways detected by both over-represent\-ation and resampling are the strongest candidates for further investigation and the pathway structure analyses in Chapter~\ref{chap:Pathways} will focus on these pathways detected by both over-representation and resampling. Particularly, those replicated across datasets or with pathway metagenes. In addition to GCPR pathways detected across these analyses, the PI3K cascade will also be investigated in Chapter~\ref{chap:Pathways}, this signalling pathway is a well characterised mediator between GCPR receptors and regulation of translation \citep{Gao2015} (both detected throughout this Chapter) and exhibited unexpected behaviour with pathway the metagenes (in Section~\ref{chapt3:metagene_results}). This pathway is activated by protein Phosphorylation states and thus inactivatino may not be detectable with expression.

However, the \gls{SLIPT} approach was shown to be predictive of which siRNA primary screen candidate partners of \textit{CDH1} were validated in a secondary screen (as shown in Section~\ref{chapt3:secondary_screen}). These results further support \gls{SLIPT} for identifying robust synthetic lethal candidates which can be validated and as a triage approach for interpreting screening experiments.

\subsubsection{Replication across Tissues}

Furthermore, synthetic lethal partners identified by \gls{SLIPT} were replicated across breast and stomach cancer. These were particularly concordant at the pathway level, as expected between tissues since synthetic lethal pathways have higher conservation between species \citep{Dixon2008}. These findings support gene functions conserved across \textit{CDH1} deficient cancers in breast and stomach tissues, presenting vulnerabilities that could be applied against molecular targets in both cancers. In addition, these analyses serve as a replication across independent patient cohorts from breast and stomach cancers, decreasing the likelihood of the synthetic lethal pathways detected being false positives or artifacts of either dataset.

Synthetic lethal pathways were also replicated across expression analyses of TCGA patient samples in heterogeneous tumours and homogeneous cell line isolates. This further supports that the subset of synthetic lethal functions detectable in experimental models \citep{Chen2014, Telford2015} would be applicable tumours of patients with \textit{CDH1} deficient cancers.

There are many gene functions replicated across breast cancer gene expression analyses. Many of these were also replicated with mutation analysis and with stomach cancer or cell line expression data. These pathways were more consistent across replication analyses than previous investigations with TCGA microarray data \citep{Kelly2013}.   

\section{Summary}

We have developed a simple, interpretable, computational approach to predict synthetic lethal partners from genomics data. The analyses focus on gene expression data as it is widely available for applications in other cancers and other disease genes, particularly those with malignant loss of function.

This approach has been applied to robustly detect synthetic lethal pathways for the E-cadherin (\textit{CDH1}) in TCGA breast cancer molecular profiles with comparisons to experimenal screening \citep{Telford2015} in cell lines, and replication in TCGA stomach cancer molecular profiles and across cell types in the cancer cell line encyclopaedia. The pathway replicated across several analyses included extracellular matrix pathways (e.g., elastic fibres formation), cell signalling (including GPCRs), and core gene regulation and translation processes crucial for the growth and proliferation of cancer cells. These pathways show evidence of non-oncogene addiction for \textit{CDH1} deficient cells and present vulnerabilities which may be exploited for specific treatment against \textit{CDH1} mutations in HCGC and sporadic cancers. There was also support for synthetic lethal pathways with \textit{CDH1} in cell adhesion and cytoskeletal processes to which \textit{CDH1} belongs, supporting the finding that synthetic lethality occurs within biological pathways \citep{Kelley2005, Boone2007}.

While translational and immune pathways detected by \gls{SLIPT} were not supported by primary siRNA screening \citep{Telford2015}, these were replicated across various analyses. Due to the differences between an experimenal cell line model \citep{, Chen2014, Fece2015}%Barretina2012
and patient molecular profiles \citep{TCGA2012, TCGA2014GC}, these would not be expected to be completely concordant. Furthermore, many pathways are difficult to test in an isolated experimental system. Nevertheless, many of the genes and pathways detected by \gls{SLIPT} are suitable to inform further investigations and triage of therapeutic targets against \textit{CDH1} deficient tumours in combination with experimenal screening.  

A characteristic of gene interaction networks is a scale-free topology leading to highly interacting hub genes, these represent important genes in a functional network. Cell surface interactions, the extracellular matrix, and cell signalling (particularly PI3K/AKT signalling) were also found to be synthetic lethal hubs with more interactions detected than other genes. This indicates that these pathways are functionally important to survival of cancer cells since they are subject to high functional redundancy, despite frequent disruptions in cancer. These pathways being involved in a disproportionate number of synthetic lethal interactions is also consistent with their detection for \textit{CDH1}.

Thus synthetic lethal pathways have been identified using TCGA patient molecular profiles%, CCLE cancer cell line expression data,
and experimenal screening results. Some these were robustly replicated across these datasets and against \textit{CDH1} mutation or expression analysis. However, there remains the need to identify actionable genes within these pathways, relationships with experimental candidates, and how these pathways may affect viability when lost. While the genes identified between these analyses were less concordant the results of the TCGA breast cancer analysis will be used to test pathway structure relationships and further examine the synthetic lethal genes detected in the following Chapter.

\clearpage

\iffalse

\paragraph{Aims}

  \begin{itemize}
   \item Pathway Structure of Candidate Synthetic Lethal Genes for \textit{\textit{CDH1}} from TCGA breast data
   
   \bigskip
   
   \item Comparisons to Experimental siRNA Screen Candidates
   
   \bigskip
   
   \item Replication of Pathways across in TCGA Stomach data
  \end{itemize}

\paragraph{Summary}

    
  \begin{itemize}
   \item We have developed a Synthetic Lethal detection method that generates a high number of synthetic lethal candidates
   
   \bigskip
   
   \item Pathways in cell signalling, extracellular matrix, and cytoskeletal functions were supported with experimental candidates and the known functions of E-cadherin
   
   \bigskip
   
   \item Several candidate pathways were supported by mutation analysis and replicated across breast and stomach cancer
   
   \bigskip
   
   \item Translation and immune functions were uniquely detected by the computational approach which may be explained by differences between patient samples and cell line models
   
   \bigskip
   
   \item There remains the need to identify actionable genes within these pathways, relationships with experimental candidates, and how these pathways may affect viability when lost
  \end{itemize}
  \fi